



Supplementary Material

SALES DATA CORRECTIONS SEE ERRATUM

UK – Veterinary Antibiotic Resistance
and Sales Surveillance Report



© Crown copyright 2017

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v.3. To view this licence visit
www.nationalarchives.gov.uk/doc/open-government-licence/version/3/ or email
PSI@nationalarchives.gsi.gov.uk

This publication is available at www.gov.uk/government/collections/veterinary-antibiotic-resistance-and-sales-surveillance

Any enquiries or correspondence regarding this publication should be sent to us at

postmaster@vmd.defra.gsi.gov.uk

www.gov.uk/organisations/veterinary-medicines-directorate

Published on 27 October 2017

SALES DATA CORRECTIONS - SEE ERRATUM

Contents

| | |
|--|-----------|
| Supplementary Material for Chapter 1 | 5 |
| S1.1: Changes in Methodology | 5 |
| Table S1.1.1. Differences between the ESVAC and VARSS methodology used in previous publications for the calculation of quantity of antibiotic sold..... | 5 |
| Figure S1.1.1: Tonnes of active ingredient of antibiotic sold for all species 1993-2016 using the original UK-VARSS methodology | 6 |
| Figure S1.1.2: Milligrams (mg) of active ingredient of antibiotic sold for food producing species per Population Correction Unit (PCU) 2012-2016 calculated using the ESVAC and original UK-VARSS methodology | 6 |
| Table S1.1.2: Comparison of UK-VARSS and ESVAC methodology for the calculation on tonnes of active ingredient sold, Population Correction Unit (PCU), and milligrams (mg) of active ingredient sold per PCU for food producing species, 2012-2016..... | 7 |
| Figure S1.1.3: Milligrams (mg) of active ingredient of antibiotic sold for food-producing species per Population Correction Unit (PCU) 2005-2016 using the ESVAC methodology | 7 |
| Table S1.1.3: Tonnes of active ingredient of antibiotic sold for all species by “other” routes of administration 2012-2016..... | 7 |
| S1.2: Population Correction Unit (PCU)..... | 8 |
| Table S1.2.1: Population correction unit (PCU) (in thousand tonnes) by food producing species and total 2012-2016 | 8 |
| Table S1.2.2: Average weights at time of treatment (kg) used to calculate the Population Correction Unit (PCU) | 9 |
| S1.3: Antibiotic Active Ingredients Authorised for Use in Animals | 10 |
| S1.4: Cascade Prescribing | 12 |
| Supplementary Material for Chapter 3 | 13 |
| S3.1: EU Harmonised Monitoring Requirements of 2013/652/EU | 13 |
| Table S3.1.1 Summary of requirements of 2013/652/EU | 13 |
| S3.2: EU Harmonised Monitoring results of Susceptibility testing in <i>E. coli</i> | 14 |
| Table S3.2.1: Resistance in <i>E. coli</i> (interpreted using both CBPs and ECVs) from broiler and turkey caecal samples..... | 14 |
| S3.3: EU Harmonised Monitoring results of Susceptibility testing in <i>Campylobacter jejuni</i> | 15 |
| Table S3.3.1: Resistance in <i>Campylobacter jejuni</i> (interpreted using both CBPs and ECVs) from broiler and turkey caecal samples | 15 |
| S3.4: EU Harmonised Monitoring results of Susceptibility testing in <i>Salmonella</i> | 16 |
| Table S3.4.1: Resistance in <i>Salmonella</i> (interpreted using both CBPs and ECVs) from broiler, layer hen and turkey caecal samples | 16 |
| S3.5: Food Business Operator <i>Salmonella</i> testing | 17 |
| Table S3.5.1 Resistance in FBO <i>Salmonella</i> in England and Wales | 17 |
| Supplementary Material for Chapter 4 | 18 |
| S4.1: Disc diffusion breakpoints, corresponding MIC breakpoints and breakpoints under review for the main bacteria covered in this report..... | 18 |

| | |
|---|----|
| Table S4.1.1: Antibiotic disc concentrations used in Northern Ireland | 21 |
| S4.2: Clinical surveillance data for isolates from bovine mastitis cases | 22 |
| Table S4.2.1 Resistance (interpreted using BSAC CBPs) in <i>Escherichia coli</i> mastitis isolates | 22 |
| Table S4.2.2: Resistance (interpreted using BSAC CBPs) of <i>staphylococci</i> and <i>streptococci</i> from mastitis cases | 23 |
| S4.3: Clinical surveillance data for isolates from respiratory infections of cattle | 24 |
| Table S4.3.1: Resistance (interpreted using BSAC CBPs) of <i>Pasteurella multocida</i> , <i>Mannheimia haemolytica</i> and <i>Trueperella pyogenes</i> from respiratory infections of cattle | 24 |
| S4.4: Clinical surveillance data for isolates from respiratory infections of pigs | 25 |
| Table S4.4.1 Resistance (interpreted using BSAC CBPs) of <i>Pasteurella multocida</i> and <i>Actinobacillus pleuropneumoniae</i> from respiratory infections of pigs | 25 |
| S4.5: Clinical surveillance data for isolates from respiratory infections of sheep | 26 |
| Table S4.5.1: Resistance (interpreted using BSAC CBPs) of <i>Pasteurella multocida</i> , <i>Mannheimia haemolytica</i> , <i>Bibersteinia trehalosi</i> and <i>Trueperella ovogenes</i> from sheep | 26 |
| S4.6: Other Veterinary Pathogens | 27 |
| Table S4.6.1: MIC values of <i>Brachyspira hyodysenteriae</i> isolates from infections of pigs to tiamulin | 27 |
| Table S4.6.2: Resistance (interpreted using BSAC CRPs) of <i>Streptococcus suis</i> from infections of pigs | 28 |
| Table S4.6.3: Resistance (interpreted using BSAC CBPs) of <i>Erysipelothrix rhusiopathiae</i> from infections of pigs | 28 |
| Table S4.6.4: Resistance (interpreted using BSAC CBPs) of <i>Staphylococcus aureus</i> from infections of chickens | 29 |
| Table S4.6.5 Resistance (interpreted using BSAC CBPs) of <i>Listeria monocytogenes</i> and <i>Streptococcus dysgalactiae</i> from infections of sheep | 29 |
| S4.7 Clinical surveillance data for <i>E. coli</i> | 30 |
| Table S4.7.1: Resistance in all <i>E. coli</i> from cattle, sheep, pigs, chickens and turkeys (combined) in England & Wales, Northern Ireland and Scotland | 30 |
| Table S4.7.2: Resistance in all <i>E. coli</i> from cattle (all ages) in England & Wales, Northern Ireland and Scotland | 31 |
| Table S4.7.3: Resistance in all <i>E. coli</i> from pigs (all ages) in England & Wales, Northern Ireland and Scotland | 32 |
| Table S4.7.4: Resistance in all <i>E. coli</i> from sheep (all ages) in England & Wales, Northern Ireland and Scotland | 33 |
| Table S4.7.5: Resistance in all <i>E. coli</i> from chickens (all ages) in England & Wales, Northern Ireland and Scotland | 34 |
| Table S4.7.6: Resistance in all <i>E. coli</i> from turkeys (all ages) in England & Wales, Northern Ireland and Scotland | 35 |
| Table S4.7.7: Resistance in <i>E. coli</i> from cattle in England & Wales, Northern Ireland and Scotland in 2014 | 36 |

| | |
|--|----|
| Table S4.7.8: Resistance in <i>E. coli</i> from cattle in England & Wales, Northern Ireland and Scotland in 2015 | 37 |
| Table S4.7.9 Resistance in <i>E. coli</i> from cattle in England & Wales, Northern Ireland and Scotland in 2016 | 38 |
| Table S4.7.10: Resistance in <i>E. coli</i> from pigs in England & Wales, Northern Ireland and Scotland in 2014 | 39 |
| Table S4.7.11: Resistance in <i>E. coli</i> from pigs in England & Wales, Northern Ireland and Scotland in 2015 | 40 |
| Table S4.7.12: Resistance in <i>E. coli</i> from pigs in England & Wales, Northern Ireland and Scotland in 2016 | 41 |
| Table S4.7.13: Resistance in <i>E. coli</i> from sheep in England & Wales, Northern Ireland and Scotland in 2014 | 42 |
| Table S4.7.14: Resistance in <i>E. coli</i> from sheep in England & Wales, Northern Ireland and Scotland in 2015 | 43 |
| Table S4.7.15: Resistance in <i>E. coli</i> from sheep in England & Wales, Northern Ireland and Scotland in 2016 | 44 |
| S4.8: Clinical surveillance data for <i>Salmonella</i> | 45 |
| Table S4.8.1: Resistance in all <i>Salmonella</i> from cattle, pigs, sheep, chickens and turkeys (combined) from clinical surveillance in England and Wales, Northern Ireland and Scotland | 45 |
| Table S4.8.2: Resistance in all <i>Salmonella</i> from cattle (all ages) from surveillance in England and Wales, Northern Ireland and Scotland | 46 |
| Table S4.8.3: Resistance in all <i>Salmonella</i> from pigs (all ages) from clinical surveillance in England and Wales, Northern Ireland and Scotland | 47 |
| Table S4.8.4: Resistance in all <i>Salmonella</i> from sheep (all ages) from clinical surveillance in England and Wales, Northern Ireland and Scotland | 48 |
| Table S4.8.5: Resistance in all <i>Salmonella</i> from chickens (all ages) from clinical surveillance in England and Wales, Northern Ireland and Scotland* | 49 |
| Table S4.8.6: Resistance in all <i>Salmonella</i> from turkeys (all ages) from clinical surveillance in England and Wales, Northern Ireland and Scotland* | 50 |
| Table S4.8.7: Resistance in all <i>Salmonella</i> Dublin from cattle, pigs, sheep, chickens and turkeys (combined) from clinical surveillance in England and Wales, Northern Ireland and Scotland* | 51 |
| Table S4.8.8: Resistance in all <i>Salmonella</i> Typhimurium from cattle, pigs, sheep, chickens and turkeys (combined) from clinical surveillance in England and Wales, Northern Ireland and Scotland** | 52 |
| Table S4.8.9: Resistance in all <i>Salmonella</i> other than Dublin and Typhimurium from cattle, pigs, sheep, chickens and turkeys (combined) from clinical surveillance in England and Wales, Northern Ireland and Scotland** | 53 |
| Table S4.8.10: Top ten <i>Salmonella</i> serovars isolated in Northern Ireland | 54 |
| Table S4.8.11: Top ten <i>Salmonella</i> serovars isolated in Scotland | 54 |

Supplementary Material for Chapter 1

S1.1: Changes in Methodology

The European Commission (EC) has requested the European Medicines Agency (EMA) to take the lead in collating data collected on the use of antibiotic agents in animals in the European Union. The EMA has therefore developed a harmonised approach for the collection and reporting of data based on national sales figures. This is designed to be comparable with usage data of human antibiotics.

Published ESVAC reports are available from:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000302.jsp

The ESVAC publications use a different method to calculate mg/PCU compared to the approach previously used in the UK. Table S1.1.1 summarises these differences, which are also highlighted in Figure S1.1.1 and Table S1.1.2.

Table S1.1.1. Differences between the ESVAC and VARSS methodology used in previous publications for the calculation of quantity of antibiotic sold

| | UK-VARSS | ESVAC |
|---|--|---|
| Products included | ↑ All authorised veterinary antibiotic products. | ↓ Topical presentations are not included. |
| Calculation of active ingredient quantity | ↓ Ingredients are converted to active moiety (the active molecule not including salts) | ↑ Active ingredient weights relate directly to information held within the SPC |
| Calculation of PCU | ↑ Horses <u>not included</u> as food producing animals | ↓ Horses <u>included</u> as food producing animals |
| Calculation of mg/PCU | ↓ Only takes into account products which are authorised for use in food producing animals <i>only</i> . Horses are excluded. Takes into account all administration routes. | ↑ All formulations (<i>for all species</i>) other than tablets included; it is considered that tablets are primarily used in the treatment of non-food producing animals. |
| Conclusion | Likely underestimates mg/PCU | Likely overestimates mg/PCU |

Key:

↑ = Increases overall mg/PCU ↓ = Decreases overall mg/PCU

In order to harmonise the national and European reporting, the ESVAC methodology has been adopted. The historical data based on the traditional UK methodology, as well as 2015 data calculated in the same way, can be seen in Figure S1.1.1.

For further details on how mg/PCU is calculated please see:

<https://www.gov.uk/government/publications/understanding-the-mgpcu-calculation-used-for-antibiotic-monitoring-in-food-producing-animals>

Data have been collected from Market Authorisation Holders since 1993, although this was only a statutory requirement from 2005. Data shown in Figure S1.1.1 represent sales of antibiotics for therapeutic use only, and do not contain sales of products marketed as growth promoters, which were banned in 2006.

Figure S1.1.1: Tonnes of active ingredient of antibiotic sold for all species 1993-2016 using the original UK-VARSS methodology



Figure S1.1.2: Milligrams (mg) of active ingredient of antibiotic sold for food producing species per Population Correction Unit (PCU) 2012-2016 calculated using the ESVAC and original UK-VARSS methodology




Table S1.1.2: Comparison of UK-VARSS and ESVAC methodology for the calculation on tonnes of active ingredient sold, Population Correction Unit (PCU), and milligrams (mg) of active ingredient sold per PCU for food producing species, 2012-2016.

| | 2012 | | 2013 | | 2014 | | 2015 | | 2016 | |
|-----------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| | VARSS | ESVAC |
| Tonnes of active ingredient | 381 | 447 | 355 | 422 | 369 | 430 | 332 | 395 | 238 | 320 |
| PCU (thousand tonnes) | 6354 | 6749 | 6404 | 6799 | 6518 | 6915 | 6584 | 6961 | 6765 | 7142 |
| mg/PCU | 60 | 66 | 55 | 62 | 57 | 62 | 50 | 57 | 35 | 45 |

Figure S1.1.3 shows historical data for mg/PCU for 2005-2016, calculated using ESVAC methodology. The data represented accounts for sales of antibiotics for food producing animals only, inclusive of horses.

Figure S1.1.3: Milligrams (mg) of active ingredient of antibiotic sold for food-producing species per Population Correction Unit (PCU) 2005-2016 using the ESVAC methodology



Table S1.1.3 shows the sales for other antibiotic products, which include topical preparations and those for sensory organs e.g. aerosols, creams, gels, shampoos and ear and eye medications (not included in ESVAC calculation).

Table S1.1.3: Tonnes of active ingredient of antibiotic sold for all species by “other” routes of administration 2012-2016

| | 2012 | 2013 | 2014 | 2015 | 2016 |
|--------|------|------|------|------|------|
| Others | 2 | 2 | 3 | 2 | 3 |

S1.2: Population Correction Unit (PCU)

When assessing antibiotic sales it is important that the demographics of the animal population potentially exposed to treatment are also taken into account, (see Annex A of the main report - data limitations). This is achieved through use of the PCU, a technical unit of measurement (where 1 PCU = 1kg of animal treated), which is calculated by multiplying a standardised average weight at time of treatment (see Table S1.2.2) with the associated annual animal/ slaughter numbers. The calculation also takes into account animals exported from the UK for slaughter, or imported to the UK for fattening. Full details on the methodology of calculation of the PCU can be found in the 2009 ESVAC report:

http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC_500112309

Table S1.2.1 shows the combined UK PCU value for food producing species and horses. The standard formula used for calculation of the PCU for poultry does not include population figures for egg producers (laying hens) so the poultry PCU is an underestimate (EMA, 2011).

Table S1.2.1: Population correction unit (PCU) (in thousand tonnes) by food producing species and total 2012-2016

| | 2012 | 2013 | 2014 | 2015 | 2016 |
|--|------|------|------|------|------|
| Total food producing species + horses* | 6749 | 6795 | 6915 | 6961 | 7142 |
| Sheep and goat | 2697 | 2730 | 2809 | 2795 | 2845 |
| Cattle | 1708 | 1692 | 1731 | 1743 | 1792 |
| Poultry | 1040 | 1059 | 1042 | 1082 | 1151 |
| Pig | 733 | 716 | 745 | 770 | 789 |
| Horses** | 395 | 395 | 395 | 378 | 378 |
| Fish | 176 | 177 | 193 | 187 | *** |

* Total food producing species PCU includes cattle, pigs, sheep, goats, poultry (broilers), fish and horses.

** Horse population data are obtained from the British Equestrian Trade Association survey which is run every 5 years.

*** UK aquaculture population statistics for 2015 are not yet available as they are collated through 2017. Therefore, for fish PCU calculation purposes, 2015 data have been used.

Companion animals are not included in the PCU as reliable population data cannot be collected and no agreed weights at time of treatment have been allocated for these species.

Table S1.2.2: Average weights at time of treatment (kg) used to calculate the Population Correction Unit (PCU)

| Animal Category | Average weight at treatment (kg) | Source |
|--|----------------------------------|--|
| Cattle | | |
| Slaughter cows | 425 | Montforts (1999) ¹ |
| Slaughter heifers | 200 | EMA ² |
| Slaughter bullocks and bulls | 425 | Montforts (1999) ¹ |
| Slaughter calves and young cattle | 140 | Montforts (1999) ¹ ; EMA ² |
| Imported/ exported cattle for slaughter | 425 | Montforts (1999) ¹ |
| Imported/ exported cattle for fattening | 140 | Montforts (1999) ¹ |
| Livestock dairy cows | 425 | Montforts (1999) ¹ ; EMA ² |
| Pigs | | |
| Slaughter pigs | 65 | Montforts (1999) ¹ |
| Imported/ exported pigs for slaughter | 65 | Montforts (1999) ¹ |
| Imported/ exported pigs for fattening | 25 | M. Goll (Eurostat, personal comm.) |
| Livestock sows | 240 | Montforts (1999) ¹ |
| Poultry | | |
| Slaughter broilers | 1 | Montforts (1999) ¹ ; EMA ² |
| Slaughter turkeys | 6.5 | Montforts (1999) ¹ ; EMA ² |
| Imported/ exported poultry for slaughter | 1 | Montforts (1999) ¹ ; EMA ² |
| Sheep and goats | | |
| Slaughter sheep and goats | 20 | Montforts (1999) ¹ |
| Imported/ exported sheep and goats for slaughter | 20 | Montforts (1999) ¹ |
| Livestock sheep | 75 | Montforts (1999) ¹ |
| Horses | | |
| Living horses | 400 | Montforts (1999) ¹ ; EMA ² |
| Fish⁵ | | |

¹ M.H.M.M. Montforts (1999). Environmental risk assessment for veterinary medicinal products. Part 1. Other than GMO-containing and immunological products. First update.

² European Medicines Agency (EMA). Revised guideline on environmental impact assessment for veterinary medicinal products in support of the VICH guidelines GL6 and GL 38 ([EMEA/CVMP/ERA/418282/2005-Rev.1](http://emea.europa.eu/pdfs/human/ewp/418282/2005-Rev.1.pdf)).

³ Assume broilers.

⁴ Assume lambs.

⁵ Data from Eurostat is given as 1,000 tonnes slaughtered fish (as live weight).

S1.3: Antibiotic Active Ingredients Authorised for Use in Animals

| Class/Active Ingredient | Authorised Species | Administration Route |
|--|---|---|
| Tetracyclines | | |
| Chlortetracycline | Cattle, Pigs, Sheep, Chickens, Turkey, Ducks | cutaneous spray, oral/water, premix |
| Doxycycline | Pigs, Chickens, Turkey, Cats, Dogs, Pigeons | tablet, oral/water, premix |
| Oxytetracycline | Cattle, Pigs, Sheep, Chickens, Salmon, Trout, Dogs, Cats, Horses | tablet, injectable, premix, oral/water, cutaneous spray |
| Tetracycline | Cattle, Pigs, Chickens | tablet, oral |
| Sul- Trim | | |
| Sulfadiazine | Cattle, Pigs, Chickens, Turkey, Cats, Dogs, Horses | tablet, oral/water, injectable, premix, intramammary suspension, |
| Sulfadimethoxine | Pigeons | oral/water |
| Sulfadimidine | Cattle, Pigs, Sheep | injectable |
| Sulfadoxine | Cattle, Horses | injectable |
| Sulfamethoxazole | Pigs, Chickens | oral/water |
| Trimethoprim | Cattle, Pigs, Chickens, Turkey, Cats, Dogs, Horses | tablet, oral/water, premix, intramammary suspension |
| Beta-lactams | | |
| <i>1st Generation Cephalosporins</i> | | |
| Cefalexin | Cattle, Cats, Dogs | tablet, injectable, intramammary suspension |
| Cefalonium | Cattle | intramammary suspension |
| Cefapirin | Cattle | intramammary suspension, intrauterine suspension |
| <i>3rd Generation Cephalosporins*</i> | | |
| Cefoperazone | Cattle | intramammary suspension |
| Cefovecin | Cats, Dogs | injectable |
| Ceftiofur | Cattle, Pigs, Horses | injectable |
| <i>4th Generation Cephalosporins*</i> | | |
| Cefquinome | Cattle, Pigs, Horses | injectable, intramammary suspension/ointment |
| <i>Penicillins</i> | | |
| Amoxicillin | Cattle, Pigs, Sheep, Chickens, Turkey, Ducks, Salmon, Cats, Dogs, Pigeons | injectable, tablet, oral/water, premix, intramammary suspension, top dressing |
| Ampicillin | Cattle, Pigs, Sheep, Cats, Dogs | injectable, tablet, intramammary suspension |
| Benzylpenicillin | Cattle, Pigs, Sheep, Chickens, Cats, Dogs, Horses | injectable, oral/water, intramammary suspension |
| Clavulanic | Cattle, Sheep, Cats, Dogs, Horses | intramammary suspension, eye ointment |
| Nafcillin | Cattle | intramammary suspension |
| Phenoxymethylenicillin | Pigs | premix |
| Aminoglycosides | | |
| Apramycin | Cattle, Pigs, Chickens | premix, oral/water |
| Dihydrostreptomycin | Cattle, Pigs, Sheep, Cats, Dogs, Horses | injectable, intramammary suspension |
| Framycetin | Cattle, Cats, Dogs | injectable, intramammary suspension, ear drops |
| Gentamicin | Cats, Dogs, Horses, Rabbits | injectable, eye drops, ear drops, gel |

| Aminoglycosides continued | | |
|---------------------------|--|--|
| Kanamycin | Cattle | intramammary suspension |
| Neomycin | Cattle, Sheep, <i>Cats, Dogs, Horses</i> | injectable, oral/water, intramammary suspension, ear drops |
| Spectinomycin | Cattle, Pigs, Sheep, Chickens | injectable, premix, oral/water |
| Streptomycin | Cattle, Sheep, <i>Cats, Dogs, Horses</i> | injectable, oral/water, intramammary suspension |
| Fluoroquinolones* | | |
| Danofloxacin | Cattle, Pigs | injectable |
| Difloxacin | Cattle, Chickens, Turkeys, <i>Dogs</i> | injectable, tablet, oral/water |
| Enrofloxacin | Cattle, Pigs, Sheep, Chickens, Turkeys, Goats, <i>Cats, Dogs, Rabbits, Reptiles, Ornamental Birds, Rodents</i> | injectable, tablet, oral/water |
| Ibafloxacin | No currently authorised products | - |
| Marbofloxacin | Cattle, Pigs, <i>Cats, Dogs</i> | tablet, injectable, ear drops |
| Orbifloxacin | <i>Dogs</i> | ear drops, oral/water |
| Pradofloxacin | <i>Cats, Dogs</i> | tablet |
| Macrolides | | |
| Erythromycin | Chickens | oral/water |
| Gamithromycin | Cattle | injectable |
| Spiramycin | Cattle, <i>Dogs, Cats</i> | injectable, tablet |
| Tildipirosin | Cattle, Pigs | injectable |
| Tilmicosin | Cattle, Pigs, Sheep, Chickens, Turkey, <i>Rabbits</i> | injectable, premix, oral/water |
| Tulathromycin | Cattle, Pigs | injectable |
| Tylosin | Cattle, Pigs, Chickens, Turkey | oral/water, premix, injectable |
| Tylvalosin | Pigs, Chickens, Turkey, Game Birds | oral/water, premix |
| Other | | |
| Amphenicols | | |
| Florfenicol | Cattle, Pigs, Sheep, Salmon | injectable, oral/water, premix, ear gel |
| Lincomycins | | |
| Lincomycin | Cattle, Pigs, Chicken, <i>Cats, Dogs</i> | oral/water, premix, injectable, intramammary solution |
| Clindamycin | <i>Cats, Dogs</i> | tablet, oral/water |
| Pirlimycin | Cattle | intramammary solution |
| Pleuromutilins | | |
| Tiamulin | Pigs, Chickens, Turkey, <i>Rabbits</i> | oral/water, premix, injectable |
| Valnemulin | Pigs, <i>Rabbits</i> | oral/water, premix |
| Polymyxins | | |
| Colistin | Cattle, Pigs, Sheep, Chickens | oral/water |
| Polymyxin B | <i>Cats, Dogs</i> | ear drops, cutaneous suspension |
| Steroidal antibiotics | | |
| Fusidic acid | <i>Cats, Dogs, Rabbits</i> | ear drops, gel |

*denotes the classes of antibiotics which are considered 'highest priority critically important antibiotics for people' (HP-CIAs) based on classification by European Medicines ad hoc expert group on AMR.

Non- food producing species are indicated in italics

S1.4: Cascade Prescribing

The Cascade is a legislative provision in the Veterinary Medicines Regulations that allows a veterinary surgeon to prescribe unauthorised medicines that would not otherwise be permitted e.g. imported medicines or a medicine licensed for another species or human use. The principle of the Cascade is that, if there is no suitable veterinary medicine authorised in the UK to treat a condition, the veterinary surgeon responsible for the animal may in particular circumstances (for example to avoid causing unacceptable suffering) treat with an unauthorised medicine. Food producing animals may only be treated under the Cascade with medicines whose pharmacologically active substances are listed in the Table of Allowed Substances in Commission Regulation EU No 37/2010.

The data used in this report do not include data on sales of imported or human antibiotics used in animals in accordance with the prescribing cascade, as currently there is no mechanism by which such information can be obtained. The understanding is that use of human products in food producing species is not extensive, due to issues with longer withdrawal periods when using such products.

The VMD continues to explore methods that can accurately incorporate information on the amounts of antibiotics imported into/exported from the UK and methods that can accurately incorporate sales of antibiotics licensed for humans that are sold for animal use under the Cascade prescribing system.

Supplementary Material for Chapter 3

S3.1: EU Harmonised Monitoring Requirements of 2013/652/EU

Table S3.1.1 Summary of requirements of 2013/652/EU

| | Sampling Year | | | | | | |
|--|---------------|------|------|------|------|------|------|
| | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
| <i>Salmonella</i> spp. - broilers | x | | x | | x | | x |
| <i>Salmonella</i> spp. - layers | x | | x | | x | | x |
| <i>Salmonella</i> spp. - fattening turkeys | x | | x | | x | | x |
| <i>Salmonella</i> spp. - broiler carcases | x | | x | | x | | x |
| <i>Salmonella</i> spp. - fattening turkey carcases | x | | x | | x | | x |
| <i>Salmonella</i> spp. - pig carcases | | x | | x | | x | |
| <i>Campylobacter jejuni</i> - broilers | x | | x | | x | | x |
| <i>Campylobacter jejuni</i> - fattening turkeys | x | | x | | x | | x |
| <i>E. coli</i> - broiler caeca | x | | x | | x | | x |
| <i>E. coli</i> - turkey caeca | x | | x | | x | | x |
| <i>E. coli</i> - pig caeca | | x | | x | | x | |
| ESBL, AmpC or carbapenemase producing <i>E. coli</i> - broiler caeca | x | | x | | x | | x |
| ESBL, AmpC or carbapenemase producing <i>E. coli</i> - turkey caeca | x | | x | | x | | x |
| ESBL, AmpC or carbapenemase producing <i>E. coli</i> - pig caeca | | x | | x | | x | |
| ESBL, AmpC or carbapenemase producing <i>E. coli</i> - fresh broiler meat, pig meat and bovine meat gathered at retail | x | x | x | x | x | x | x |
| <i>Campylobacter coli</i> - broilers | x | | x | | x | | x |
| <i>Campylobacter coli</i> - pig | | x | | x | | x | |
| <i>E. faecium</i> and <i>E. faecalis</i> - broilers, fattening turkeys, fattening pigs, bovines <1yr age | x | x | x | x | x | x | x |

| Key: |
|----------------|
| x = Mandatory |
| x = Voluntary |
| Pig and Bovine |
| Poultry |

Note: The UK is exempt from the monitoring of resistance in isolates of bovine origin as we do not meet the cattle (<1 year of age) slaughter throughput as specified in the legislation.

S3.2: EU Harmonised Monitoring results of Susceptibility testing in *E. coli*

Table S3.2.1: Resistance in *E. coli* (interpreted using both CBPs and ECVs) from broiler and turkey caecal samples

| Antibiotic | No. of isolates resistant (Percentage resistant) | | | | | | | |
|-----------------|--|------------|----------------|------------|-----------------|------------|----------------|------------|
| | 2014 | | | | 2016 | | | |
| | Broiler (n=159) | | Turkey (n=168) | | Broiler (n=190) | | Turkey (n=224) | |
| | CBPs | ECVs | CBPs | ECVs | CBPs | ECVs | CBPs | ECVs |
| Ampicillin | 116 (73) | 116 (73) | 116 (69) | 116 (69) | 128 (67.4) | 128 (67.4) | 136 (60.7) | 136 (60.7) |
| Azithromycin | - | - | - | - | - | - | - | - |
| Cefotaxime | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0.4) | 1 (0.4) |
| Ceftazidime | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0.4) | 1 (0.4) |
| Chloramphenicol | 20 (12.6) | 14 (8.8) | 20 (11.9) | 17 (10.1) | 13 (6.3) | 7 (3.7) | 20 (8.9) | 17 (7.6) |
| Ciprofloxacin | 6 (3.8) | 39 (24.5) | 12 (7.1) | 29 (17.3) | 5 (1.6) | 41 (21.6) | 11 (4.9) | 35 (15.6) |
| Colistin | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Gentamicin | 31 (19.5) | 32 (20.1) | 7 (4.2) | 7 (4.2) | 13 (6.8) | 14 (7.4) | 5 (2.2) | 5 (2.2) |
| Meropenem | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Nalidixic acid | 39 (24.5) | 39 (24.5) | 31 (18.5) | 31 (18.5) | 40 (21.1) | 40 (21.1) | 32 (14.3) | 32 (14.3) |
| Sulphonamide | * | 104 (65.4) | * | 54 (32.1) | * | 100 (52.6) | * | 57 (25.4) |
| Tetracyclines | 97 (61) | 97 (61) | 132 (78.6) | 132 (78.6) | 84 (44.2) | 84 (44.2) | 150 (67) | 150 (67) |
| Tigecycline | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Trimethoprim | 75 (47.2) | 75 (47.2) | 40 (23.8) | 40 (23.8) | 81 (42.6) | 81 (42.6) | 51 (22.8) | 51 (22.8) |

*No clinical breakpoint value available.

- Not applicable

S3.3: EU Harmonised Monitoring results of Susceptibility testing in *Campylobacter jejuni*

Table S3.3.1: Resistance in *Campylobacter jejuni* (interpreted using both CBPs and ECVs) from broiler and turkey caecal samples

| Antibiotic | No. of isolates resistant (Percentage resistant) | | | | | | | |
|----------------|--|-----------|----------------|----------|-----------------|------------|----------------|-----------|
| | 2014 | | | | 2016 | | | |
| | Broiler (n=165) | | Turkey (n=157) | | Broiler (n=180) | | Turkey (n=190) | |
| | CBPs | ECVs | CBPs | ECVs | CBPs | ECVs | CBPs | ECVs |
| Ciprofloxacin | 72 (43.6) | 72 (43.6) | 55 (35) | 55 (35) | 73 (40.6) | 73 (40.6) | 66 (34.7) | 66 (34.7) |
| Erythromycin | 0 (0) | 0 (0) | 1 (0.6) | 1 (0.6) | 1 (0.6) | 1 (0.6) | 2 (1.1) | 2 (1.1) |
| Gentamicin | * | 0 (0) | * | 2 (1.3) | * | 0 (0) | * | 0 (0) |
| Nalidixic acid | * | 73 (44.2) | * | 55 (35) | * | 74 (41.1) | * | 62 (32.6) |
| Streptomycin | * | 0 (0) | * | 2 (1.3) | * | 2 (1.1) | * | 3 (1.6) |
| Tetracyclines | 95 (57.6) | 97 (58.8) | 102 (65) | 102 (65) | 101 (56.1) | 101 (56.1) | 79 (41.6) | 82 (43.2) |

*No clinical breakpoint value available.

S3.4: EU Harmonised Monitoring results of Susceptibility testing in *Salmonella*

Table S3.4.1: Resistance in *Salmonella* (interpreted using both CBPs and ECVs) from broiler, layer hen and turkey caecal samples

| Antibiotic | No. of isolates resistant (Percentage resistant) | | | | | | | | | | | |
|-----------------|--|-----------|-----------------|-----------|--------------|---------|--------------|----------|----------------|-----------|----------------|------------|
| | 2014 | | 2016 | | 2014 | | 2016 | | 2014 | | 2016 | |
| | Broiler (n=168) | | Broiler (n=170) | | Layer (n=58) | | Layer (n=34) | | Turkey (n=162) | | Turkey (n=169) | |
| Antibiotic | CBPs | ECVs | CBPs | ECVs | CBPs | ECVs | CBPs | ECVs | CBPs | ECVs | CBPs | ECVs |
| Ampicillin | 6 (3.6) | 6 (3.6) | 6 (3.5) | 6 (3.5) | 0 (0) | 0 (0) | 2 (5.7) | 2 (5.7) | 37 (22.8) | 37 (22.8) | 9 (5.3) | 9 (5.3) |
| Azithromycin | - | - | - | - | - | - | - | - | - | - | - | - |
| Cefotaxime | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Ceftazidime | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Chloramphenicol | 12 (7.1) | 2 (1.2) | 10 (5.9) | 1 (0.6) | 1 (1.7) | 0 (0) | 1 (2.9) | 0 (0) | 25 (15.4) | 1 (0.6) | 5 (3) | 1 (0.6) |
| Ciprofloxacin | 0 (0) | 6 (3.6) | 1 (0.6) | 15 (8.8) | 0 (0) | 1 (1.7) | 0 (0) | 3 (8.8) | 0 (0) | 33 (20.4) | 0 (0) | 3 (1.8) |
| Colistin | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (5.2) | 3 (5.2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Gentamicin | 12 (7.2) | 14 (8.3) | 2 (1.2) | 2 (1.2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0.6) | 1 (0.6) |
| Meropenem | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (5) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Nalidixic acid | 6 (3.6) | 6 (3.6) | 6 (3.5) | 6 (3.5) | 1 (1.7) | 1 (1.7) | 1 (2.9) | 1 (2.9) | 33 (20.4) | 33 (20.4) | 3 (1.8) | 3 (1.8) |
| Sulphonamide | * | 52 (31) | * | 31 (18.2) | * | 0 (0) | * | 4 (11.8) | * | 74 (45.7) | * | 126 (74.6) |
| Tetracyclines | 34 (20.2) | 34 (20.2) | 33 (19.4) | 33 (19.4) | 0 (0) | 0 (0) | 2 (5.7) | 2 (5.7) | 79 (48.8) | 79 (48.8) | 128 (75.7) | 128 (75.7) |
| Tigecycline | 0 (0) | 10 (6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (1.9) | 13 (8) | 0 (0) | 0 (0) |
| Trimethoprim | 32 (19) | 32 (19) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2.9) | 1 (2.9) | 12 (7.4) | 12 (7.4) | 4 (2.4) | 4 (2.4) |

*No clinical breakpoint value available

- Not applicable

S3.5: Food Business Operator *Salmonella* testing

Table S3.5.1 Resistance in FBO *Salmonella* in England and Wales

| Antibiotic | No. resistant / No. tested (Percentage resistant) |
|-----------------|--|
| | England & Wales 2016 |
| Ampicillin | 0/17 (0) |
| Azithromycin | 0/17 (0) |
| Cefotaxime | 0/17 (0) |
| Ceftazidime | 0/17 (0) |
| Chloramphenicol | 0/17 (0) |
| Ciprofloxacin | 0/17 (0) |
| Colistin | 0/17 (0) |
| Gentamicin | 0/17 (0) |
| Meropenem | 0/17 (0) |
| Nalidixic acid | 0/17 (0) |
| Sulphonamide | 2/17 (11.8) |
| Tetracyclines | 1/17 (5.9) |
| Tigecycline | 0/17 (0) |
| Trimethoprim | 2/17 (11.8) |

Supplementary Material for Chapter 4

S4.1: Disc diffusion breakpoints, corresponding MIC breakpoints and breakpoints under review for the main bacteria covered in this report.

| Antibiotic | Disc Charge (micrograms) | <i>Escherichia coli</i> , Enterobacteriaceae | Salmonella | Staphylococci | Streptococci | <i>Pasteurella, Mannheimia, Histophilus, Actinobacillus</i> |
|------------------------------------|--------------------------|--|-------------------------|---------------------|---------------------|---|
| Amikacin (AK) | 30 | R ≤ 18mm R ≥ 16mg/l | R ≤ 18mm R ≥ 16mg/l | NA | NA | NA |
| Amoxicillin/ clavulanic acid (AMC) | 20/10 | R ≤ 14mm R>8mg/l | R ≤ 14mm R>8mg/l | NA | NA | R ≤ 13mm |
| Amoxicillin/ clavulanic acid | 2/1 | NA | NA | R ≤ 17mm R>1mg/l | R ≤ 13mm | NA |
| Ampicillin (AM) | 10 | R ≤ 14mm R>8mg/l | R ≤ 14mm R>8mg/l | R ≤ 13mm | R ≤ 13mm | R ≤ 29mm R>1mg/l |
| Apramycin (APR) | 15 | R ≤ 13mm R ≥ 32 mg/l | R ≤ 13mm R ≥ 32 mg/l | NA | NA | R ≤ 13mm [†] |
| Cefotaxime (CTX) | 30 | R ≤ 29mm R≥2mg/l | R ≤ 29mm R≥2mg/l | NA | NA | NA |
| Cefpodoxime | 10 | R ≤ 17mm R>1mg/l | NA | NA | NA | R ≤ 13mm |
| Ceftazidime (CAZ) | 30 | R ≤ 26mm R ≥ 2mg/l | R ≤ 26mm R ≥ 2mg/l | NA | NA | NA |
| Cefalexin | 30 | R ≤ 15mm R>16mg/l | NA | R ≤ 13mm | R ≤ 24mm R>2mg/l | R ≤ 13mm |
| Chloramphenicol (C) | 30 | R ≤ 20mm R>8mg/l | R ≤ 20mm R>8mg/l | NA | NA | NA |

| Antibiotic | Disc Charge (micrograms) | <i>Escherichia coli</i> , Enterobacteriaceae | Salmonella | Staphylococci | Streptococci | <i>Pasteurella, Mannheimia,</i> <i>Histophilus, Actinobacillus</i> |
|---------------------|-----------------------------|---|-----------------------|--------------------------|----------------------------|---|
| Ciprofloxacin (CIP) | 1 | NA | R ≤ 16mm R ≥ 1mg/l | NA | NA | NA |
| Doxycycline | 30 | R ≤ 13mm | NA | R ≤ 30mm R ≥ 2mg/l | NA | R ≤ 13mm |
| Erythromycin | 5 | NA | NA | R ≤ 19mm R ≥ 2mg/l | R ≤ 21mm* R ≥ 0.5mg/l | R ≤ 13mm |
| Enrofloxacin | 5 | R ≤ 13mm R ≥ 4mg/l | NA | R ≤ 13mm | R ≤ 13mm | R ≤ 13mm |
| Florfenicol | 30 | R ≤ 13mm R > 32mg/l | NA | NA | R ≤ 13mm | R ≤ 13mm |
| Furazolidone (FR) | 15 | NA | ≤ 13mm | NA | NA | NA |
| Gentamicin (CN) | 10 | NA | R ≤ 19mm R ≥ 4mg/l | NA | NA | NA |
| Lincomycin | 10 | NA | NA | R ≤ 13mm | R ≤ 13mm | R ≤ 13mm |
| Nalidixic acid (NA) | NA | NA | ≤ 13mm | NA | NA | NA |
| Neomycin (N) | 10 | R ≤ 13mm R > 8mg/l | R ≤ 13mm R > 8mg/l | NA | NA | NA |
| Neomycin | 30 | NA | NA | R ≤ 13mm | R ≤ 13mm | NA |
| Novobiocin | 30 | NA | NA | R ≤ 13mm | R ≤ 13mm | NA |
| Penicillin | 1IU | NA | NA | R ≤ 24mm R > 0.12mg/l | R ≤ 19mm** R > 0.25mg/l | R ≤ 21mm R > 0.12 mg/l |
| Spectinomycin | 25 | R ≤ 13mm | NA | NA | NA | R ≤ 13mm† |

| Antibiotic | Disc Charge (micrograms) | <i>Escherichia coli</i> , Enterobacteriaceae | <i>Salmonella</i> | <i>Staphylococci</i> | <i>Streptococci</i> | <i>Pasteurella, Mannheimia, Histophilus, Actinobacillus</i> |
|------------------------------------|-----------------------------|---|------------------------|-----------------------|--------------------------|---|
| Streptomycin (S) | 10 | R ≤ 12mm R > 8mg/l | R ≤ 13mm R > ~8mg/l | NA | NA | R ≤ 13mm [†] |
| Sulphonamide compounds (SU) | 300 | NA | ≤ 13mm | NA | NA | NA |
| Tetracycline (T) | 10 | R ≤ 13mm R > 8mg/l | R ≤ 13mm R > 8mg/l | R ≤ 19mm R ≥ 2mg/l | R ≤ 19mm*** R ≥ 2mg/l | R ≤ 25mm |
| Trimethoprim/ sulphonamide (TM) | 25 | R ≤ 15mm R ≥ 4mg/l | R ≤ 15mm R ≥ 4mg/l | R ≤ 16mm R ≥ 4mg/l | R ≤ 19mm R ≥ 2mg/l | R ≤ 13mm |
| Tylosin | 30 | NA | NA | R ≤ 13mm | R ≤ 13mm | R ≤ 13mm |

Key:

- BSAC human clinical breakpoint
- Animal and Plant Health Agency (APHA) historical veterinary disc diffusion zone size breakpoint and MIC corresponding to that zone size breakpoint
- Animal Health and Veterinary Laboratories Agency (AHVLA) historical veterinary breakpoint (under ongoing review)

Notes:

Where zone size disc diffusion data collected using the BSAC method and MIC data are both available then it is possible to draw regression lines and investigate the MIC which approximately corresponds to the historical veterinary breakpoint of 13mm. This has been done for several compounds (highlighted in blue in the table above).

BSAC state that all *Salmonella* isolates should be reported as resistant to gentamicin and amikacin; resistance traits are used for epidemiological purposes (correlation with particular resistance mechanisms) in this report.

The 16 antibiotics with antibiotic code e.g. amikacin (AK) are the set used for *Salmonella* susceptibility testing.

Some *Haemophilus-Pasteurella-Actinobacillus* i.e. "HPA" organisms, for example *Actinobacillus pleuropneumoniae*, show a degree of intrinsic resistance to aminoglycosides.

* Erythromycin R ≤ 21mm for beta-haemolytic streptococci; R ≤ 19mm for other streptococci.

** Penicillin R ≤ 19mm for beta-haemolytic streptococci; R ≤ 16mm for other streptococci.

*** Tetracycline R ≤ 19mm for beta-haemolytic streptococci; R ≤ 23mm for other streptococci

Table S4.1.1: Antibiotic disc concentrations used in Northern Ireland

| Antibiotic | Disc | Expected Zone diameter (mm) | | |
|-----------------|--------|-----------------------------|---------------|-------------|
| | | Resistant | Intermediate | Susceptible |
| Ampicillin | AMP10 | <=13 | 14-16 | >=17 |
| Chloramphenicol | C30 | <=12 | 13-17 | >=18 |
| Gentamicin | CN10 | <=12 | 13-14 | >=15 |
| Kanamycin | K30 | <=13 | 14-17 | >=18 |
| Streptomycin | S10 | <=11 | 12-14 | >=15 |
| Sulphonamides | S3.300 | <=12 | 13-16 | >=17 |
| Tetracycline | TE30 | <=11 | 12-14 | >=15 |
| Trimethoprim | W5 | <=10 | 11-15 | >=16 |
| Furazolidone | FR100 | | Not available | >=17 |
| Nalidixic acid | NA30 | <=13 | 14-18 | >=19 |
| Ciprofloxacin | CIP5 | <=15 | 16-20 | >=21 |
| Cefotaxime | CTX30 | <=22 | 23-25 | >=26 |
| Ceftazidime | CAZ30 | <=17 | 18-20 | >=21 |
| Amoxicillin | AMC30 | <=13 | 14-17 | >=18 |
| Framycetin | FY100 | | Not available | |
| Apramycin | APR15 | | Not available | |
| Spectinomycin | SH100 | | Not available | |

S4.2: Clinical surveillance data for isolates from bovine mastitis cases

Table S4.2.1 Resistance (interpreted using BSAC CBPs) in *Escherichia coli* mastitis isolates

| Antibiotic | No. (%) of isolates resistant | | |
|-----------------|-------------------------------|--------------|---------------|
| | 2014 | 2015 | 2016 |
| Amoxi/Clav | 11/149 (7.4) | 13/88 (14.8) | 6/106 (5.7) |
| Ampicillin | 36/149 (24.2) | 23/88 (26.1) | 29/106 (27.4) |
| Cefotaxime | - | - | - |
| Cefpodoxime | 3/149 (2) | 2/88 (2.3) | 0/106 (0) |
| Ceftazidime | - | - | - |
| Cefalexin | - | - | - |
| Enrofloxacin | 4/149 (2.7) | 0/88 (0) | 2/106 (1.9) |
| Neomycin | 6/149 (4) | 4/88 (4.5) | 8/106 (7.5) |
| Streptomycin | 14/149 (9.4) | 11/88 (12.5) | 15/106 (14.2) |
| Tetracycline | 17/149 (11.4) | 16/88 (18.2) | 18/106 (17) |
| Trimetho/Sulpho | 13/149 (8.7) | 9/88 (10.2) | 14/106 (13.2) |

- No isolates tested

Table S4.2.2: Resistance (interpreted using BSAC CBPs) of *staphylococci* and *streptococci* from mastitis cases

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | | | |
|--------------|---|--------------|-------------|-----------------------------|---------------|--------------|-----------------------------------|--------------|--------------|
| | <i>Staphylococcus aureus</i> | | | <i>Streptococcus uberis</i> | | | <i>Streptococcus dysgalactiae</i> | | |
| | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 |
| Amoxi/Clav | 12/82 (14.6) | 9/77 (11.7) | 4/62 (6.5) | 0/122 (0) | 0/123 (0) | 0/94 (0) | 0/41 (0) | 0/36 (0) | 0/41 (0) |
| Ampicillin | 29/82 (35.4) | 25/77 (32.5) | 7/62 (11.3) | 0/122 (0) | 0/123 (0) | 0/94 (0) | 0/41 (0) | 0/36 (0) | 0/41 (0) |
| Penicillin | 29/82 (35.4) | 25/77 (32.5) | 8/62 (12.9) | 0/122 (0) | 0/123 (0) | 0/94 (0) | 0/41 (0) | 0/36 (0) | 0/41 (0) |
| Neomycin | 0/82 (0) | 2/77 (2.6) | 0/62 (0) | 72/121 (59.5) | 79/119 (66.4) | 47/93 (50.5) | 10/41 (24.4) | 3/36 (8.3) | 10/40 (25) |
| Novobiocin | 1/82 (1.2) | 0/77 (0) | 0/62 (0) | 11/121 (9.1) | 10/119 (8.4) | 6/93 (6.5) | 2/41 (4.9) | 1/36 (2.8) | 4/40 (10) |
| Tetracycline | 3/82 (3.7) | 4/77 (5.2) | 1/62 (1.6) | 66/122 (54.1) | 62/123 (50.4) | 37/94 (39.4) | 35/41 (85.4) | 34/36 (94.4) | 40/41 (97.6) |
| Tylosin | 1/82 (1.2) | 2/77 (2.6) | 0/62 (0) | 20/122 (16.4) | 14/123 (11.4) | 8/94 (8.5) | 4/41 (9.8) | 2/36 (5.6) | 4/41 (10) |

S4.3: Clinical surveillance data for isolates from respiratory infections of cattle

Table S4.3.1: Resistance (interpreted using BSAC CBPs) of *Pasteurella multocida*, *Mannheimia haemolytica* and *Trueperella pyogenes* from respiratory infections of cattle*

| Antibiotic | No. (%) of isolates resistant | | | | | | | | |
|-----------------------------|-------------------------------|--------------|--------------|-----------------------|------------|------------|--------------------|------------|----------|
| | <i>P. multocida</i> | | | <i>M. haemolytica</i> | | | <i>T. pyogenes</i> | | |
| | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 |
| Amoxicillin/Clavulanic acid | 0/29 (0) | 0/42 (0) | 0/76 (0) | 0/12 (0) | 0/28 (0) | 0/35 (0) | 0/13 (0) | 0/8 (0) | 0/4 (0) |
| Ampicillin | 1/29 (3.4) | 0/42 (0) | 2/76 (2.6) | 0/12 (0) | 1/28 (3.6) | 0/35 (0) | 0/13 (0) | 0/8 (0) | 0/4 (0) |
| Cefalexin | - | - | - | - | - | - | 0/13 (0) | 0/8 (0) | 0/4 (0) |
| Cefpodoxime | 0/29 (0) | 0/42 (0) | 0/76 (0) | 0/12 (0) | 0/28 (0) | 0/35 (0) | - | - | - |
| Enrofloxacin | 0/29 (0) | 0/42 (0) | 0/76 (0) | 0/12 (0) | 0/28 (0) | 0/35 (0) | - | - | - |
| Florfenicol | 0/29 (0) | 1/42 (2.5) | 2/70 (2.8) | 2/12 (16.7) | 0/28 (0) | 1/35 (2.8) | 0/13 (0) | 0/8 (0) | 0/4 (0) |
| Tetracycline | 9/29 (31) | 16/42 (38.1) | 44/76 (57.8) | 3/12 (25) | 0/28 (0) | 3/35 (8.6) | 8/13 (61.5) | 5/8 (62.5) | 2/4 (50) |
| Trimethoprim/Sulphonamide | 0/29 (0) | 1/42 (2.4) | 0/76 (0) | 0/12 (0) | 0/28 (0) | 0/35 (0) | 3/13 (23.1) | 3/8 (37.5) | 0/4 (0) |
| Tylosin | - | - | - | - | - | - | 0/13 (0) | 1/8 (12.5) | 1/4 (25) |

*No resistant *H. somni* isolates were detected between the years 2014 and 2016 and are, therefore, not included in this table.

- No isolates tested

S4.4: Clinical surveillance data for isolates from respiratory infections of pigs

Table S4.4.1 Resistance (interpreted using BSAC CBPs) of *Pasteurella multocida* and *Actinobacillus pleuropneumoniae* from respiratory infections of pigs

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | |
|-----------------------------|---|-------------|--------------|----------------------------------|--------------|-------------|
| | Pigs, <i>P. multocida</i> | | | Pigs, <i>A. pleuropneumoniae</i> | | |
| | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 |
| Amoxicillin/Clavulanic acid | 0/27 (0) | 0/11 (0) | 0/19 (0) | 0/14 (0) | 0/22 (0) | 0/14 (0) |
| Ampicillin | 1/33 (3) | 0/12 (0) | 6/31 (19.3) | 0/14 (0) | 2/22 (9.1) | 1/15 (6.7) |
| Apramycin | 1/32 (3.1) | 0/12 (0) | 1/31 (3.2) | 4/14 (28.6) | 2/22 (9.1) | 3/15 (20) |
| Cefpodoxime | 0/32 (0) | 0/12 (0) | 0/31 (0) | 0/14 (0) | 0/22 (0) | 0/15 (0) |
| Doxycycline | 0/27 (0) | 0/11 (0) | 0/19 (0) | 0/14 (0) | 0/22 (0) | 0/14 (0) |
| Enrofloxacin | 0/33 (0) | 0/12 (0) | 0/31 (0) | 0/14 (0) | 0/22 (0) | 0/15 (0) |
| Florfenicol | 0/27 (0) | 0/11 (0) | 0/19 (0) | 0/14 (0) | 0/22 (0) | 0/14 (0) |
| Lincomycin | - | - | - | - | - | - |
| Neomycin | 0/32 (0) | 1/12 (8.3) | 3/31 (9.7) | 5/14 (35.7) | 2/22 (9.1) | 3/15 (20) |
| Spectinomycin | 0/32 (0) | 0/12 (0) | 0/31 (0) | 4/14 (28.6) | 2/22 (9.1) | 2/15 (13.3) |
| Streptomycin | 3/27 (11.1) | 2/11 (18.2) | 6/19 (31.5) | 5/14 (35.7) | 2/22 (9.1) | 2/14 (14.3) |
| Tetracycline | 27/33 (81.8) | 8/12 (66.7) | 25/31 (80.6) | 4/14 (28.6) | 8/22 (36.4) | 7/15 (46.7) |
| Trimethoprim/Sulphonamide | 11/33 (33.3) | 1/12 (8.3) | 7/31 (22.6) | 0/14 (0) | 9/22 (40.9) | 7/15 (46.7) |
| Tylosin | 1/28 (3.6) | 3/11 (27.3) | 7/19 (36.8) | 13/14 (92.9) | 20/22 (90.9) | 14/14 (100) |

- No isolates tested

S4.5: Clinical surveillance data for isolates from respiratory infections of sheep

Table S4.5.1: Resistance (interpreted using BSAC CBPs) of *Pasteurella multocida*, *Mannheimia haemolytica*, *Bibersteinia trehalosi* and *Trueperella pyogenes* from sheep

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | | | | | | |
|-----------------------------|---|------------|----------|------------------------------|------------|------------|----------------------------|------------|------------|---------------------------|---------|----------|
| | Sheep, <i>P. multocida</i> | | | Sheep, <i>M. haemolytica</i> | | | Sheep, <i>B. trehalosi</i> | | | Sheep, <i>T. pyogenes</i> | | |
| | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 |
| Amoxicillin/Clavulanic acid | 0/2 (0) | 0/3 (0) | 0/4 (0) | 0/24 (0) | 0/35 (0) | 0/49 (0) | 0/21 (0) | 0/40 (0) | 0/95 (0) | 0/10 (0) | 0/1 (0) | 0/2 (0) |
| Ampicillin | 0/2 (0) | 1/3 (33.3) | 0/4 (0) | 0/24 (0) | 0/35 (0) | 0/49 (0) | 0/21 (0) | 0/40 (0) | 0/95 (0) | 0/10 (0) | 0/1 (0) | 0/2 (0) |
| Cefalexin | - | - | - | - | - | - | - | - | - | 0/10 (0) | 0/1 (0) | 0/2 (0) |
| Cefpodoxime | 0/2 (0) | 0/3 (0) | 0/4 (0) | 0/24 (0) | 0/35 (0) | 0/49 (0) | 0/21 (0) | 0/40 (0) | 0/95 (0) | - | - | - |
| Enrofloxacin | 0/2 (0) | 0/3 (0) | 0/4 (0) | 0/24 (0) | 0/35 (0) | 0/49 (0) | 0/21 (0) | 0/40 (0) | 1/95 (1.1) | - | - | - |
| Florfenicol | 0/2 (0) | 0/3 (0) | 0/4 (0) | 0/23 (0) | 0/35 (0) | 0/47 (0) | 0/21 (0) | 0/40 (0) | 0/95 (0) | 0/9 (0) | 0/1 (0) | 0/2 (0) |
| Tetracycline | 0/2 (0) | 0/3 (0) | 2/4 (50) | 2/24 (8.3) | 1/35 (2.9) | 2/49 (4.1) | 0/21 (0) | 1/40 (2.5) | 2/95 (2.1) | 2/10 (20) | 0/1 (0) | 1/2 (50) |
| Trimethoprim/Sulphonamide | 0/2 (0) | 0/3 (0) | 0/4 (0) | 1/24 (4.2) | 1/35 (2.9) | 0/49 (0) | 0/21 (0) | 1/40 (2.5) | 0/95 (0) | 4/9 (44.4) | 0/1 (0) | 0/2 (0) |
| Tylosin | - | - | - | - | - | - | - | - | - | 0/10 (0) | 0/1 (0) | 1/2 (50) |

- No isolates tested

S4.6: Other Veterinary Pathogens

Table S4.6.1: MIC values of *Brachyspira hyodysenteriae* isolates from infections of pigs to tiamulin

| Year | MIC | | | | | | | | |
|------|-------|------|------|-----|---|---|---|---|----|
| | <0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | >8 |
| 2010 | 10 | 1 | - | 1 | 1 | - | - | - | - |
| 2011 | 10 | - | - | - | - | 2 | - | - | - |
| 2012 | 2 | - | 2 | - | - | 2 | 1 | - | 2 |
| 2013 | - | - | 1 | 2 | 1 | - | 1 | - | 3 |
| 2014 | - | - | - | - | - | 2 | - | 1 | 1 |
| 2015 | - | - | 3 | - | - | 1 | - | 1 | - |
| 2016 | 1 | - | - | - | 1 | - | 1 | - | - |

Table S4.6.2: Resistance (interpreted using BSAC CBPs) of *Streptococcus suis* from infections of pigs

| Antibiotic | No. (%) of isolates resistant | | |
|---------------------------|-------------------------------|--------------|--------------|
| | Pigs, <i>S. suis</i> | | |
| | 2014 | 2015 | 2016 |
| Ampicillin | 0/64 (0) | 0/63 (0) | 0/86 (0) |
| Penicillin | 0/64 (0) | 0/63 (0) | 0/86 (0) |
| Cefalexin | - | - | - |
| Enrofloxacin | 0/64 (0) | 0/63 (0) | 0/86 (0) |
| Lincomycin | 21/64 (32.8) | 26/63 (41.3) | 30/86 (34.9) |
| Tetracycline | 61/64 (95.3) | 59/63 (93.7) | 78/86 (90.7) |
| Trimethoprim/Sulphonamide | 15/64 (23.4) | 14/63 (22.2) | 11/56 (12.8) |
| Tylosin | 24/64 (37.5) | 37/63 (58.7) | 37/56 (43) |

- No isolates tested

Table S4.6.3: Resistance (interpreted using BSAC CBPs) of *Erysipelothrix rhusiopathiae* from infections of pigs

| Antibiotic | No. (%) of isolates resistant | | |
|-----------------------------|-------------------------------|------------|-------------|
| | Pigs, <i>E. rhusiopathiae</i> | | |
| | 2014 | 2015 | 2016 |
| Amoxicillin/Clavulanic acid | - | - | - |
| Ampicillin | 0/11 (0) | 0/6 (0) | 0/18 (0) |
| Enrofloxacin | 1/11 (9.1) | 0/6 (0) | 0/18 (0) |
| Lincomycin | 0/11 (0) | 0/6 (0) | 0/18 (0) |
| Tetracycline | 3/11 (27.3) | 2/6 (33.3) | 6/18 (33.3) |
| Trimethoprim/Sulphonamide | 2/11 (18.2) | 2/6 (33.3) | 8/18 (44.4) |
| Tylosin | 0/11 (0) | 0/6 (0) | 0/18 (0) |

- No isolates tested

Table S4.6.4: Resistance (interpreted using BSAC CBPs) of *Staphylococcus aureus* from infections of chickens

| Antibiotic | No. (%) of isolates resistant | | |
|-----------------------------|-------------------------------|------------|------------|
| | Chickens, <i>S. aureus</i> | | |
| | 2014 | 2015 | 2016 |
| Amoxicillin/Clavulanic acid | 0/26 (0) | 0/8 (0) | 1/12 (8.3) |
| Ampicillin | 0/26 (0) | 0/8 (0) | 1/15 (6.7) |
| Doxycycline | 2/26 (7.7) | 0/8 (0) | 1/15 (6.7) |
| Enrofloxacin | 0/26 (0) | 0/8 (0) | 1/15 (6.7) |
| Erythromycin | 2/26 (8) | 1/8 (12.5) | 1/12 (8.3) |
| Lincomycin | 2/26 (7.7) | 1/8 (12.5) | 0/15 (0) |
| Tetracycline | 3/26 (11.5) | 1/8 (12.5) | 3/15 (20) |
| Trimethoprim/Sulphonamide | 0/26 (0) | 0/8 (0) | 0/15 (0) |
| Tylosin | 0/26 (0) | 0/8 (0) | 1/15 (6.7) |

Table S4.6.5 Resistance (interpreted using BSAC CBPs) of *Listeria monocytogenes* and *Streptococcus dysgalactiae* from infections of sheep

| Antibiotic | No. (%) of isolates resistant | | | | | |
|-----------------------------|--------------------------------------|----------|-------------|--|-------------|--------------|
| | Sheep, <i>Listeria monocytogenes</i> | | | Sheep, <i>Streptococcus dysgalactiae</i> | | |
| | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 |
| Amoxicillin/Clavulanic acid | 0/2 (0) | 0/4 (0) | 0/49 (0) | 0/14 (0) | 0/18 (0) | 0/35 (0) |
| Ampicillin | 0/2 (0) | 0/4 (0) | 0/49 (0) | 0/14 (0) | 0/18 (0) | 0/35 (0) |
| Cefalexin | 0/2 (0) | 3/4 (75) | 7/49 (14.3) | 0/14 (0) | 0/18 (0) | 0/35 (0) |
| Florfenicol | 0/2 (0) | 0/4 (0) | 0/49 (0) | 0/14 (0) | 0/18 (0) | 0/35 (0) |
| Tetracycline | 1/2 (50) | 0/4 (0) | 2/49 (4.1) | 14/14 (100) | 18/18 (100) | 34/35 (97.1) |
| Trimethoprim/Sulphonamide | 0/2 (0) | 0/4 (0) | 0/49 (0) | 0/14 (0) | 0/18 (0) | 0/35 (0) |
| Tylosin | 0/2 (0) | 0/4 (0) | 0/49 (0) | 3/14 (21.4) | 0/18 (0) | 4/35 (11.4) |

S4.7 Clinical surveillance data for *E. coli*

Table S4.7.1: Resistance in all *E. coli* from cattle, sheep, pigs, chickens and turkeys (combined) in England & Wales, Northern Ireland and Scotland

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | | | |
|-----------------|---|-----------------|-----------------|------------------|----------------|----------------|----------------|----------------|----------------|
| | England & Wales | | | Northern Ireland | | | Scotland | | |
| | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 |
| Amikacin | 2/590 (0.3) | 3/524 (0.6) | 4/467 (0.9) | - | - | - | - | - | - |
| Amoxi/Clav | 314/1045 (30) | 282/1034 (27.3) | 221/1123 (19.7) | 496/986 (50.3) | 471/931 (50.6) | 504/906 (55.6) | 72/293 (24.6) | 69/346 (19.9) | 69/485 (14.2) |
| Ampicillin | 733/1144 (64.1) | 713/1101 (64.8) | 683/1200 (56.7) | 798/986 (80.9) | 719/931 (80.3) | 733/906 (80.9) | 136/293 (46.4) | 130/346 (37.6) | 183/484 (37.8) |
| Apramycin | 73/1118 (6.5) | 60/1073 (5.6) | 68/1135 (6) | 116/980 (11.8) | 138/917 (15) | 97/865 (11.2) | 3/236 (1.3) | 3/271 (1.1) | 7/426 (1.6) |
| Cefotaxime | 80/593 (13.5) | 49/526 (9.3) | 62/469 (13.2) | - | - | - | - | - | - |
| Cefpodoxime | 19/481 (4) | 34/474 (7.2) | 7/314 (2.2) | 396/980 (10.4) | 403/912 (44.2) | 387/891 (43.4) | 12/236 (5.1) | 8/271 (3) | 12/427 (2.8) |
| Ceftazidime | 44/593 (7.4) | 34/526 (6.5) | 41/469 (8.7) | - | - | - | - | - | - |
| Chloramphenicol | 298/590 (50.5) | 244/524 (46.6) | 200/467 (42.8) | - | - | - | 0/2 (0) | 0/1 (0) | 0/4 (0) |
| Doxycycline | 157/452 (34.7) | 132/451 (29.3) | 165/538 (30.7) | - | - | - | - | - | - |
| Enrofloxacin | 93/1144 (8.1) | 118/1101 (10.7) | 78/1200 (6.5) | 418/986 (42.4) | 414/931 (44.5) | 380/908 (41.9) | 13/293 (4.4) | 12/346 (3.5) | 17/485 (3.5) |
| Florfenicol | 209/764 (27.4) | 174/709 (24.5) | 164/792 (20.7) | 448/919 (48.7) | 413/878 (47) | 404/808 (50) | 33/223 (14.8) | 28/257 (10.9) | 31/202 (15.4) |
| Neomycin | 287/1049 (27.4) | 266/1030 (25.8) | 249/1100 (22.6) | 986/986 (100) | 932/932 (100) | 583/586 (99.5) | 26/293 (8.9) | 26/346 (7.5) | 28/485 (5.8) |
| Spectinomycin | 441/1118 (39.4) | 462/1073 (43.1) | 423/1135 (37.3) | - | - | 3/35 (8.6) | 56/236 (23.7) | 60/271 (22.1) | 78/426 (18.3) |
| Streptomycin | 442/742 (59.6) | 443/685 (64.7) | 394/743 (53) | - | - | 33/33 (100) | 7/55 (12.7) | 2/73 (2.7) | 4/54 (7.4) |
| Tetracycline | 779/1144 (68.1) | 708/1101 (64.3) | 727/1200 (60.6) | 770/986 (78.1) | 745/927 (80.4) | 687/907 (75.7) | 169/293 (57.7) | 160/346 (46.2) | 175/485 (36.1) |
| Trimetho/Sulpho | 442/1144 (38.6) | 420/1101 (38.1) | 461/1200 (38.4) | 629/986 (63.8) | 615/926 (66.4) | 551/907 (60.7) | 76/293 (25.9) | 64/346 (18.5) | 99/485 (20.4) |

- No isolates tested

Table S4.7.2: Resistance in all *E. coli* from cattle (all ages) in England & Wales, Northern Ireland and Scotland

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | | | |
|-----------------|---|----------------|----------------|------------------|---------------|----------------|---------------|---------------|---------------|
| | England & Wales | | | Northern Ireland | | | Scotland | | |
| | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 |
| Amikacin | 2/492 (0.4) | 2/441 (0.5) | 3/365 (0.8) | - | - | - | - | - | - |
| Amoxi/Clav | 271/533 (50.8) | 223/494 (45.1) | 175/450 (38.9) | 424/733 (58) | 443/714 (62) | 410/685 (59.9) | 61/146 (41.8) | 44/150 (29.3) | 48/161 (29.8) |
| Ampicillin | 431/533 (80.9) | 392/494 (79.4) | 343/450 (76.2) | 630/732 (86) | 602/714 (84) | 571/634 (83.5) | 76/146 (52.1) | 58/150 (38.7) | 76/161 (47.2) |
| Apramycin | 22/517 (4.3) | 22/480 (4.6) | 17/425 (4) | 83/729 (11) | 105/709 (15) | 71/655 (10.8) | 2/90 (2.2) | 2/77 (2.6) | 3/102 (2.9) |
| Cefotaxime | 77/495 (15.6) | 46/443 (10.4) | 58/367 (15.8) | - | - | - | - | - | - |
| Cefpodoxime | - | - | - | 308/731 (42) | 328/704 (47) | 304/680 (44.7) | 12/90 (13.3) | 0/78 (0) | 10/103 (9.7) |
| Ceftazidime | 42/495 (8.5) | 32/443 (7.2) | 38/367 (10.3) | - | - | - | - | - | - |
| Chloramphenicol | 271/492 (55.1) | 228/441 (51.7) | 173/365 (47.4) | - | - | - | 0/1 (0) | - | 0/4 (0) |
| Doxycycline | - | - | - | - | - | - | - | - | - |
| Enrofloxacin | 60/533 (11.3) | 58/494 (11.7) | 47/450 (10.4) | 368/732 (50) | 361/714 (51) | 337/686 (49.1) | 11/146 (7.5) | 6/150 (4) | 13/161 (8.1) |
| Florfenicol | 190/507 (37.5) | 147/455 (32.3) | 132/392 (33.7) | 216/728 (57) | 402/712 (56) | 373/653 (57.1) | 32/90 (35.6) | 22/77 (28.6) | 28/104 (26.9) |
| Neomycin | 250/517 (48.4) | 217/480 (45.2) | 174/425 (40.9) | 732/732 (100) | 714/714 (100) | 420/422 (99.5) | 21/146 (14.4) | 20/150 (13.3) | 22/161 (13.7) |
| Spectinomycin | 231/517 (44.7) | 218/480 (45.4) | 166/425 (39.1) | - | - | 2/33 (6.1) | 34/90 (37.8) | 29/77 (37.7) | 31/102 (30.4) |
| Streptomycin | 316/492 (64.2) | 315/441 (71.4) | 221/365 (60.5) | - | - | 31/31 (100) | 7/55 (12.7) | 1/72 (2.4) | 4/54 (7.4) |
| Tetracycline | 424/533 (79.5) | 369/494 (74.7) | 331/450 (73.6) | 597/732 (82) | 593/711 (83) | 542/685 (79.1) | 81/146 (55.5) | 65/150 (43.3) | 74/161 (46) |
| Trimetho/Sulph | 261/533 (49) | 224/494 (45.3) | 210/450 (46.7) | 503/732 (69) | 505/711 (71) | 452/685 (66) | 43/146 (29.5) | 26/150 (17.3) | 39/161 (24.2) |

- No isolates tested

Table S4.7.3: Resistance in all *E. coli* from pigs (all ages) in England & Wales, Northern Ireland and Scotland

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | | | |
|-----------------|---|----------------|----------------|------------------|-------------|--------------|-------------|-------------|--------------|
| | England & Wales | | | Northern Ireland | | | Scotland | | |
| | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 |
| Amikacin | - | - | - | - | - | - | - | - | - |
| Amoxi/Clav | 6/151 (4) | 8/159 (5) | 11/267 (4.1) | 33/101 (33) | 21/93 (23) | 39/77 (50.6) | 3/11 (27.3) | 5/22 (22.7) | 4/28 (14.3) |
| Ampicillin | 104/180 (57.8) | 102/182 (56) | 165/300 (55) | 71/101 (70) | 67/93 (72) | 31/78 (78.2) | 6/11 (54.5) | 6/22 (27.3) | 9/28 (32.1) |
| Apramycin | 34/180 (18.9) | 31/182 (17) | 40/300 (13.3) | 20/100 (20) | 20/93 (22) | 12/77 (16.9) | 0/11 (0) | 0/22 (0) | 0/28 (0) |
| Cefotaxime | - | - | - | - | - | - | - | - | - |
| Cefpodoxime | 7/180 (3.9) | 3/182 (1.6) | 7/300 (2.3) | 28/100 (28) | 26/93 (28) | 19/77 (24.7) | 0/11 (0) | 0/21 (0) | 0/28 (0) |
| Ceftazidime | - | - | - | - | - | - | - | - | - |
| Chloramphenicol | - | - | - | - | - | - | - | - | - |
| Doxycycline | 90/151 (59.6) | 79/159 (49.7) | 128/267 (47.9) | - | - | - | - | - | - |
| Enrofloxacin | 17/180 (9.4) | 7/182 (3.8) | 17/300 (5.7) | 23/101 (23) | 28/93 (30) | 16/78 (20.5) | 0/11 (0) | 2/22 (9.1) | 3/28 (10.7) |
| Florfenicol | 8/151 (5.3) | 16/159 (10.1) | 21/267 (7.9) | 12/100 (12) | 12/93 (13) | 8/77 (10.4) | 0/11 (0) | 1/22 (4.5) | 0/28 (0) |
| Neomycin | 7/180 (3.9) | 15/182 (8.2) | 19/300 (6.3) | 101/101 (100) | 93/93 (100) | 74/74 (100) | 0/11 (0) | 0/22 (0) | 0/28 (0) |
| Spectinomycin | 86/180 (47.8) | 78/182 (42.9) | 138/300 (46) | - | - | - | 5/11 (45.4) | 3/22 (13.6) | 6/28 (21.4) |
| Streptomycin | 82/151 (54.3) | 71/159 (44.7) | 116/267 (43.4) | - | - | - | - | - | - |
| Tetracycline | 142/180 (78.9) | 121/182 (66.5) | 99/300 (66.3) | 81/101 (80) | 76/93 (82) | 60/78 (76.9) | 8/11 (72.7) | 9/22 (40.9) | 12/28 (42.9) |
| Trimetho/Sulph | 102/180 (56.7) | 99/182 (54.4) | 163/300 (54.3) | 79/101 (78) | 70/92 (76) | 50/78 (64.1) | 6/11 (54.5) | 3/22 (13.6) | 11/28 (39.3) |

- No isolates tested

Table S4.7.4: Resistance in all *E. coli* from sheep (all ages) in England & Wales, Northern Ireland and Scotland

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | | | |
|-----------------|---|---------------|---------------|------------------|-------------|--------------|--------------|--------------|--------------|
| | England & Wales | | | Northern Ireland | | | Scotland | | |
| | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 |
| Amikacin | 0/98 (0) | 1/83 (1.2) | 1/102 (1) | - | - | - | - | - | - |
| Amoxi/Clav | 26/130 (20) | 21/133 (15.8) | 26/179 (14.5) | 23/83 (28) | 24/66 (36) | 30/69 (44.1) | 8/29 (27.6) | 11/48 (22.9) | 13/70 (18.6) |
| Ampicillin | 71/130 (54.6) | 74/133 (55.6) | 86/179 (48) | 60/83 (72) | 44/66 (67) | 54/69 (79.4) | 11/29 (37.9) | 19/48 (39.6) | 27/70 (38.6) |
| Apramycin | 3/120 (2.5) | 1/119 (0.8) | 5/139 (3.6) | 8/83 (10) | 7/66 (11) | 6/67 (9) | 0/28 (0) | 1/46 (2.2) | 0/70 (0) |
| Cefotaxime | 3/98 (3.1) | 3/83 (3.6) | 4/102 (3.9) | - | - | - | - | - | - |
| Cefpodoxime | - | - | - | 30/83 (36) | 25/66 (38) | 21/68 (30.9) | 0/28 (0) | 0/46 (0) | 2/70 (2.9) |
| Ceftazidime | 2/98 (2) | 2/83 (2.4) | 3/102 (2.9) | - | - | - | - | - | - |
| Chloramphenicol | 27/98 (27.6) | 16/83 (19.3) | 27/102 (26.5) | - | - | - | 0/1 (0) | 0/1 (0) | - |
| Doxycycline | - | - | - | - | - | - | - | - | - |
| Enrofloxacin | 1/130 (0.8) | 2/133 (1.5) | 7/179 (3.9) | 13/83 (22) | 11/66 (17) | 9/68 (13.2) | 0/29 (0) | 2/48 (3.6) | 1/70 (1.4) |
| Florfenicol | 11/106 (10.4) | 11/95 (11.6) | 11/133 (8.3) | 19/83 (23) | 19/66 (29) | 16/67 (23.9) | 1/28 (3.6) | 5/44 (11.4) | 3/70 (4.3) |
| Neomycin | 9/121 (7.4) | 21/121 (17.4) | 23/148 (15.5) | 83/83 (100) | 66/66 (100) | 38/38 (100) | 4/29 (13.8) | 4/48 (8.3) | 5/70 (7.1) |
| Spectinomycin | 52/120 (43.3) | 67/119 (56.3) | 63/139 (45.3) | - | - | - | 7/28 (25) | 13/46 (28.3) | 18/70 (25.7) |
| Streptomycin | 44/99 (44.4) | 57/85 (67.1) | 57/111 (51.4) | - | - | - | - | 1/1 (100) | - |
| Tetracycline | 89/130 (68.5) | 86/133 (64.7) | 11/179 (62) | 60/83 (72) | 48/66 (72) | 47/68 (69.1) | 18/29 (62.1) | 26/48 (54.2) | 34/70 (48.6) |
| Trimetho/Sulph | 28/130 (21.5) | 36/133 (27.1) | 39/179 (21.8) | 32/83 (39) | 22/66 (33) | 26/68 (38.2) | 7/29 (24.1) | 7/48 (14.6) | 12/70 (17.1) |

- No isolates tested

Table S4.7.5: Resistance in all *E. coli* from chickens (all ages) in England & Wales, Northern Ireland and Scotland

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | | | |
|-----------------|---|----------------|---------------|------------------|-------------|--------------|--------------|---------------|---------------|
| | England & Wales | | | Northern Ireland | | | Scotland | | |
| | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 |
| Amikacin | - | - | - | - | - | - | - | - | - |
| Amoxi/Clav | 11/230 (4.8) | 30/248 (12.1) | 8/223 (3.6) | 3/33 (9) | 5/25 (20) | 5/30 (16.7) | 0/94 (0) | 9/114 (7.9) | 4/212 (1.9) |
| Ampicillin | 124/294 (42.2) | 143/287 (49.8) | 82/264 (31.1) | 16/33 (48) | 18/26 (72) | 18/30 (43.3) | 32/94 (34) | 38/114 (33.3) | 63/212 (29.7) |
| Apramycin | 14/294 (4.8) | 6/287 (2.1) | 6/264 (2.3) | 1/33 (3) | 2/26 (8) | 1/30 (3.3) | 1/94 (1.1) | 0/114 (0) | 3/212 (1.4) |
| Cefotaxime | - | - | - | - | - | - | - | - | - |
| Cefpodoxime | 12/294 (4.1) | 31/287 (10.8) | 9/264 (3.4) | 14/33 (42) | 14/26 (54) | 21/31 (67.7) | 0/94 (0) | 8/114 (7) | 0/212 (0) |
| Ceftazidime | - | - | - | - | - | - | - | - | - |
| Chloramphenicol | - | - | - | - | - | - | - | - | - |
| Doxycycline | 65/294 (22.1) | 49/287 (17.1) | 34/264 (12.9) | - | - | - | - | - | - |
| Enrofloxacin | 14/294 (4.8) | 50/287 (17.4) | 7/264 (2.7) | 3/33 (9) | 6/26 (23) | 6/30 (20) | 1/94 (1.1) | 1/114 (0.9) | 0/212 (0) |
| Florfenicol | - | - | - | - | - | 3/3 (100) | 0/94 (0) | 0/114 (0) | - |
| Neomycin | 21/230 (9.1) | 13/247 (5.3) | 32/223 (14.5) | 33/33 (100) | 26/26 (100) | 15/15 (100) | 1/94 (1.1) | 2/114 (1.8) | 1/212 (0.5) |
| Spectinomycin | 71/294 (24.1) | 99/287 (34.5) | 53/264 (20.1) | - | - | - | 9/94 (9.6) | 14/114 (12.3) | 20/212 (9.4) |
| Streptomycin | - | - | - | - | - | - | - | - | - |
| Tetracycline | 120/294 (40.8) | 128/287 (44.6) | 31/264 (30.7) | 12/33 (36) | 13/26 (50) | 11/30 (36.7) | 52/94 (55.3) | 52/114 (45.6) | 47/212 (22.2) |
| Trimetho/Sulph | 50/294 (17) | 60/287 (20.9) | 43/264 (18.1) | 5/33 (15) | 7/26 (27) | 5/30 (16.7) | 18/94 (19.1) | 20/114 (17.5) | 31/212 (14.6) |

- No isolates tested

Table S4.7.6: Resistance in all *E. coli* from turkeys (all ages) in England & Wales, Northern Ireland and Scotland

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | | | |
|-----------------|---|----------|------------|------------------|-----------|------------|--------------|-------------|-------------|
| | England & Wales | | | Northern Ireland | | | Scotland | | |
| | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 |
| Amikacin | - | - | - | - | - | - | - | - | - |
| Amoxi/Clav | 0/1 (0) | - | 1/4 (25) | 2/7 (29) | 1/3 (33) | 3/8 (37.5) | 0/13 (0) | 0/12 (0) | 0/14 (0) |
| Ampicillin | 3/7 (42.9) | 2/5 (40) | 7/7 (100) | 5/7 (71) | 2/3 (66) | 7/3 (87.5) | 11/13 (84.6) | 9/12 (75) | 8/13 (61.5) |
| Apramycin | 0/7 (0) | 0/5 (0) | 0/7 (0) | 0/7 (0) | 1/3 (33) | 3/3 (37.5) | 0/13 (0) | 0/12 (0) | 1/14 (7.1) |
| Cefotaxime | - | - | - | - | - | - | - | - | - |
| Cefpodoxime | 0/7 (0) | 0/5 (0) | 0/7 (0) | 2/7 (29) | 2/3 (66) | 6/8 (75) | 0/13 (0) | 0/12 (0) | 0/14 (0) |
| Ceftazidime | - | - | - | - | - | - | - | - | - |
| Chloramphenicol | - | - | - | - | - | - | - | - | - |
| Doxycycline | 2/7 (28.6) | 4/5 (80) | 3/7 (42.9) | - | - | - | - | - | - |
| Enrofloxacin | 1/7 (14.3) | 1/5 (20) | 0/7 (0) | 1/7 (0.1) | - | 2/8 (25) | 1/13 (7.7) | 1/12 (8.3) | 0/14 (0) |
| Florfenicol | - | - | - | - | - | - | - | - | - |
| Neomycin | 0/1 (0) | - | 1/4 (25) | 7/7 (100) | 3/3 (100) | 6/6 (100) | 0/13 (0) | 0/12 (0) | 0/14 (0) |
| Spectinomycin | 1/7 (14.3) | 0/5 (0) | 3/7 (42.9) | - | - | - | 1/13 (7.7) | 1/12 (8.3) | 3/14 (21.4) |
| Streptomycin | - | - | - | - | - | - | - | - | - |
| Tetracycline | 4/7 (57.1) | 4/5 (80) | 5/7 (71.4) | 6/7 (86) | 2/3 (66) | 6/8 (75) | 10/13 (76.9) | 8/12 (66.7) | 8/14 (57.1) |
| Trimetho/Sulph | 1/7 (14.3) | 1/5 (20) | 1/1 (14.3) | 2/7 (29) | 2/3 (66) | 3/8 (37.5) | 2/13 (7.7) | 8/12 (66.7) | 6/14 (42.9) |

- No isolates tested

Table S4.7.7: Resistance in *E. coli* from cattle in England & Wales, Northern Ireland and Scotland in 2014

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | |
|-----------------|---|--------------|------------|-------------------------------|---------------|--------------|----------|
| | England & Wales | | | Northern Ireland ¹ | Scotland | | |
| | Neonatal | Pre-weaning | Adult | Neonatal | Neonatal | Pre-weaning | Adult |
| Amikacin | 2/432 (0.5) | 0/28 (0) | 0/3 (0) | - | - | - | - |
| Amoxi/Clav | 231/449 (51.4) | 20/44 (45.5) | 2/8 (25) | 207/321 (64) | 25/103 (34) | 25/37 (67.6) | 1/5 (20) |
| Ampicillin | 365/449 (81.3) | 32/44 (72.7) | 6/8 (75) | 287/321 (89) | 46/103 (44.7) | 28/37 (75.7) | 2/5 (40) |
| Apramycin | 20/442 (4.5) | 2/37 (5.4) | 0/7 (0) | 43/320 (13) | 1/52 (1.9) | 1/37 (2.7) | - |
| Cefotaxime | 64/432 (14.8) | 7/28 (25) | 4/6 (66.7) | - | - | - | - |
| Ceftazidime | 32/432 (7.4) | 5/28 (17.9) | 3/6 (50) | - | - | - | - |
| Chloramphenicol | 237/432 (54.9) | 12/28 (42.9) | 3/3 (100) | - | 1/1 (100) | - | - |
| Enrofloxacin | 52/449 (11.6) | 4/44 (9.1) | 2/8 (25) | 103/321 (51) | 5/103 (4.9) | 6/37 (16.2) | 0/5 (0) |
| Florfenicol | 163/439 (37.1) | 10/35 (28.6) | 2/3 (66.7) | 187/320 (58) | 14/52 (26.9) | 18/37 (48.6) | - |
| Neomycin | 218/442 (49.3) | 18/37 (48.6) | 1/7 (14.3) | 321/321 (100) | 11/103 (10.7) | 10/37 (27) | 0/5 (0) |
| Spectinomycin | 204/442 (46.2) | 11/37 (29.7) | 1/7 (14.3) | - | 18/52 (34.6) | 16/37 (43.2) | - |
| Streptomycin | 278/432 (64.4) | 14/28 (50) | 2/3 (66.7) | - | 7/50 (14) | - | 0/5 (0) |
| Tetracycline | 357/449 (79.5) | 37/44 (84.1) | 5/8 (62.5) | 260/321 (81) | 45/103 (43.7) | 33/37 (89.2) | 2/5 (40) |
| Trim/Sulpho | 217/449 (48.3) | 22/44 (50) | 3/8 (37.5) | 223/321 (69) | 23/103 (22.3) | 19/37 (51.4) | 1/5 (20) |

¹ No pre-weaning or adult data available for Northern Ireland.

- No isolates tested

Table S4.7.8: Resistance in *E. coli* from cattle in England & Wales, Northern Ireland and Scotland in 2015

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | |
|-----------------|---|--------------|--------------|-------------------------------|---------------|-------------|------------|
| | England & Wales | | | Northern Ireland ¹ | Scotland | | |
| | Neonatal | Pre-weaning | Adult | | Neonatal | Pre-weaning | Adult |
| Amikacin | 2/352 (0.6) | 0/59 (0) | 0/7 (0) | - | - | - | - |
| Amoxi/Clav | 181/376 (48.1) | 23/75 (30.7) | 5/15 (33.3) | 201/331 (61) | 23/114 (24.6) | 15/30 (50) | 1/6 (16.7) |
| Ampicillin | 310/376 (82.4) | 52/75 (69.3) | 10/15 (66.7) | 296/331 (89) | 40/114 (35.1) | 16/30 (1.9) | 2/6 (33.3) |
| Apramycin | 12/369 (3.3) | 8/73 (11) | 1/13 (7.7) | 34/329 (10) | 2/45 (4.4) | 0/30 (0) | 0/2 (0) |
| Cefotaxime | 37/352 (10.5) | 3/59 (5.1) | 2/9 (22.2) | - | - | - | - |
| Ceftazidime | 28/352 (8) | 2/59 (3.4) | 1/9 (11.1) | - | - | - | - |
| Chloramphenicol | 174/352 (49.4) | 35/59 (59.3) | 3/7 (42.9) | - | - | - | - |
| Enrofloxacin | 38/376 (10.1) | 11/75 (14.7) | 4/15 (26.7) | 167/331 (50) | 2/114 (1.8) | 4/30 (7.5) | 0/6 (0) |
| Florfenicol | 105/359 (29.2) | 25/61 (41) | 3/9 (33.3) | 187/331 (56) | 10/45 (22.2) | 12/30 (2.5) | 0/2 (0) |
| Neomycin | 161/369 (43.6) | 39/73 (53.4) | 6/13 (46.2) | 331/331 (100) | 11/114 (9.6) | 8/30 (3.75) | 1/6 (16.7) |
| Spectinomycin | 173/369 (46.9) | 29/73 (39.7) | 4/13 (30.8) | - | 20/45 (44.4) | 8/30 (3.75) | 1/2 (50) |
| Streptomycin | 250/352 (71) | 46/59 (78) | 4/7 (57.1) | - | 1/68 (1.5) | - | 0/4 (0) |
| Tetracycline | 284/376 (75.5) | 55/75 (73.3) | 11/15 (73.3) | 284/331 (86) | 46/114 (40.4) | 18/30 (1.7) | 1/6 (16.7) |
| Trim/Sulpho | 168/376 (44.7) | 34/75 (45.3) | 7/15 (46.7) | 245/331 (74) | 17/114 (14.9) | 9/30 (3.3) | 0/6 (0) |

¹ No pre-weaning or adult data available for Northern Ireland.

- No isolates tested

Table S4.7.9 Resistance in *E. coli* from cattle in England & Wales, Northern Ireland and Scotland in 2016

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | |
|-----------------|---|--------------|-------------|-------------------------------|---------------|--------------|-------------|
| | England & Wales | | | Northern Ireland ¹ | Scotland | | |
| | Neonatal | Pre-weaning | Adult | Neonatal | Neonatal | Pre-weaning | Adult |
| Amikacin | 3/305 (1) | 0/33 (0) | 0/1 (0) | - | - | - | - |
| Amoxi/Clav | 136/336 (40.5) | 30/62 (48.4) | 0/16 (0) | 338/524 (64.5) | 33/103 (32) | 11/38 (29) | 4/20 (20) |
| Ampicillin | 266/336 (79.2) | 53/62 (85.5) | 5/16 (31.3) | 457/523 (87.4) | 48/103 (46.6) | 20/38 (52.6) | 8/20 (40) |
| Apramycin | 15/328 (4.6) | 1/54 (1.9) | 0/12 (0) | 60/525 (11.4) | 3/52 (5.8) | 0/35 (0) | 0/15 (0) |
| Cefotaxime | 49/306 (16) | 5/34 (14.7) | 0/1 (0) | - | - | - | - |
| Ceftazidime | 31/306 (10.1) | 5/34 (14.7) | 0/1 (0) | - | - | - | 0/3 (0) |
| Chloramphenicol | 147/305 (48.2) | 12/33 (36.4) | 0/1 (0) | - | 0/1 (0) | 0/3 (0) | - |
| Enrofloxacin | 35/336 (10.4) | 8/62 (12.9) | 2/16 (12.5) | 227/525 (43.2) | 6/103 (5.8) | 4/38 (10.5) | 3/20 (15) |
| Florfenicol | 107/314 (34.1) | 12/42 (28.6) | 0/5 (0) | 308/525 (58.7) | 11/53 (20.8) | 14/35 (40) | 3/16 (18.8) |
| Neomycin | 145/328 (44.2) | 18/54 (33.3) | 1/12 (8.3) | 337/338 (99.7) | 10/103 (9.7) | 10/38 (26.3) | 2/20 (10) |
| Spectinomycin | 131/328 (39.9) | 21/54 (38.9) | 3/12 (25) | - | 18/52 (34.6) | 11/35 (31.4) | 2/15 (13.3) |
| Streptomycin | 186/305 (61) | 20/33 (60.6) | 1/1 (100) | - | 3/50 (6) | - | 1/4 (25) |
| Tetracycline | 257/336 (76.5) | 47/62 (75.8) | 7/16 (43.8) | 437/524 (83.4) | 44/103 (42.7) | 24/38 (63.2) | 6/20 (30) |
| Trim/Sulpho | 161/336 (47.9) | 29/62 (46.8) | 6/16 (37.5) | 365/524 (69.7) | 19/103 (18.5) | 17/38 (44.7) | 3/20 (15) |

¹ No pre-weaning or adult data available for Northern Ireland.

- No isolates tested

Table S4.7.10: Resistance in *E. coli* from pigs in England & Wales, Northern Ireland and Scotland in 2014

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | |
|----------------|---|--------------|------------|-------------------------------|------------|---------------|-----------|
| | England & Wales | | | Northern Ireland ¹ | Scotland | | |
| | Neonatal | Post-weaning | Adult | Neonatal | Neonatal | Post--weaning | Adult |
| Amoxi/Clav | 0/25 (0) | 3/78 (3.8) | 0/6 (0) | 11/43 (26) | 2/7 (28.6) | 0/1 (0) | 0/1 (0) |
| Ampicillin | 19/39 (48.7) | 51/84 (60.7) | 3/7 (42.9) | 28/43 (65) | 3/7 (42.9) | 0/1 (0) | 1/1 (100) |
| Apramycin | 1/39 (2.6) | 31/84 (36.9) | 0/7 (0) | 8/43 (19) | 0/7 (0) | 0/1 (0) | 0/1 (0) |
| Cefpodoxime | 0/39 (0) | 1/84 (1.2) | 0/7 (0) | 9/43 (21) | 0/7 (0) | 0/1 (0) | - |
| Doxycycline | 12/25 (48) | 51/78 (65.4) | 3/6 (50) | - | - | - | - |
| Enrofloxacin | 7/39 (17.9) | 5/84 (6) | 1/7 (14.3) | 10/43 (23) | 0/7 (0) | 0/1 (0) | 0/1 (0) |
| Florfenicol | 1/25 (4) | 4/78 (5.1) | 0/6 (0) | 9/43 (21) | 0/7 (0) | 0/1 (0) | 0/1 (0) |
| Neomycin | 2/39 (5.1) | 2/84 (2.4) | 1/7 (14.3) | 43/43 (100) | 0/7 (0) | 0/1 (0) | 0/1 (0) |
| Spectinomycin | 20/39 (51.3) | 44/84 (52.4) | 3/7 (42.9) | - | 3/7 (42.9) | 1/1 (100) | 0/1 (0) |
| Streptomycin | 10/25 (40) | 49/78 (62.8) | 3/6 (50) | - | - | - | - |
| Tetracycline | 30/39 (76.9) | 69/84 (82.1) | 5/7 (71.4) | 33/43 (77) | 5/7 (71.4) | 1/1 (100) | 0/1 (0) |
| Trimetho/Sulph | 19/39 (48.7) | 54/84 (64.3) | 2/7 (28.6) | 40/43 (93) | 3/7 (42.9) | 1/1 (100) | 0/1 (0) |

¹ No post-weaning or adult data available for Northern Ireland.

- No isolates tested

Table S4.7.11: Resistance in *E. coli* from pigs in England & Wales, Northern Ireland and Scotland in 2015

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | |
|----------------|---|--------------|------------|-------------------------------|----------|---------------|-----------|
| | England & Wales | | | Northern Ireland ¹ | Scotland | | |
| | Neonatal | Post-weaning | Adult | Neonatal | Neonatal | Post--weaning | Adult |
| Amoxi/Clav | 2/30 (6.7) | 4/93 (4.3) | 1/7 (14.3) | 10/47 (21) | 1/5 (20) | 3/15 (20) | 1/1 (100) |
| Ampicillin | 18/39 (46.2) | 63/97 (64.9) | 3/7 (42.9) | 36/47 (77) | 1/5 (20) | 4/15 (26.7) | 1/1 (100) |
| Apramycin | 0/39 (0) | 25/97 (25.8) | 0/7 (0) | 10/47 (21) | 0/5 (0) | 0/15 (0) | 1/1 (0) |
| Cefpodoxime | 0/39 (0) | 2/97 (2.1) | 0/7 (0) | 9/47 (19) | 0/5 (0) | 0/15 (0) | - |
| Doxycycline | 13/30 (43.3) | 51/93 (54.8) | 2/7 (28.6) | - | - | - | - |
| Enrofloxacin | 1/39 (2.6) | 5/97 (5.2) | 0/7 (0) | 10/47 (34) | 0/5 (0) | 2/15 (13.3) | 0/1 (0) |
| Florfenicol | 1/30 (3.3) | 13/93 (14) | 1/7 (14.3) | 4/47 (9) | 0/5 (0) | 0/15 (0) | 1/1 (100) |
| Neomycin | 1/39 (2.6) | 12/97 (12.4) | 0/7 (0) | 47/47 (100) | 0/5 (0) | 0/15 (0) | 0/1 (0) |
| Spectinomycin | 15/39 (38.5) | 48/97 (49.5) | 2/7 (23.6) | - | 0/5 (0) | 0/15 (0) | 0/1 (0) |
| Streptomycin | 10/30 (33.3) | 45/93 (48.4) | 4/7 (57.1) | - | - | - | - |
| Tetracycline | 28/39 (71.8) | 67/97 (69.1) | 3/7 (42.9) | 40/47 (85) | 3/5 (60) | 5/15 (33.3) | 1/1 (100) |
| Trimetho/Sulph | 17/39 (43.6) | 63/97 (64.9) | 3/7 (42.9) | 37/47 (78) | 0/5 (0) | 3/15 (20) | 0/1 (0) |

¹ No post-weaning or adult data available for Northern Ireland.

- No isolates tested

Table S4.7.12: Resistance in *E. coli* from pigs in England & Wales, Northern Ireland and Scotland in 2016

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | |
|----------------|---|----------------|-----------|-------------------------------|------------|--------------|------------|
| | England & Wales | | | Northern Ireland ¹ | Scotland | | |
| | Neonatal | Post-weaning | Adult | | Neonatal | Post-weaning | Adult |
| Amoxi/Clav | 2/62 (3.2) | 8/155 (5.2) | - | 12/21 (57.1) | 0/3 (0) | 3/19 (15.8) | 1/6 (16.7) |
| Ampicillin | 40/71 (56.3) | 94/168 (56) | 1/1 (100) | 14/21 (66.7) | 1/3 (33.3) | 7/19 (36.8) | 1/6 (16.7) |
| Apramycin | 1/71 (1.4) | 33/168 (19.6) | 0/1 (0) | 6/21 (28.6) | 0/3 (0) | 0/19 (0) | 0/6 (0) |
| Cefpodoxime | 2/71 (2.8) | 4/168 (2.4) | 0/1 (0) | 6/21 (28.6) | 0/3 (0) | 0/19 (0) | 0/6 (0) |
| Doxycycline | 33/62 (53.2) | 78/155 (50.3) | - | - | - | - | - |
| Enrofloxacin | 9/71 (12.7) | 4/168 (2.4) | 0/1 (0) | 6/21 (28.6) | 1/3 (33.3) | 2/19 (10.5) | 0/6 (0) |
| Florfenicol | 3/62 (4.8) | 15/155 (9.7) | - | 2/21 (9.5) | 0/3 (0) | 0/19 (0) | 0/6 (0) |
| Neomycin | 3/71 (4.2) | 12/168 (7.1) | 0/1 (0) | 21/21 (100) | 0/3 (0) | 0/19 (0) | 0/6 (0) |
| Spectinomycin | 29/71 (40.8) | 88/168 (52.4) | 0/1 (0) | - | 1/3 (33.3) | 4/19 (21.1) | 1/6 (16.7) |
| Streptomycin | 22/62 (35.5) | 71/155 (45.8) | - | - | - | - | - |
| Tetracycline | 51/71 (71.8) | 116/168 (69) | 0/1 (0) | 17/21 (81) | 2/3 (66.7) | 9/19 (47.4) | 1/6 (16.7) |
| Trimetho/Sulph | 36/71 (50.7) | 101/168 (60.1) | 0/1 (0) | 14/21 (66.7) | 3/3 (100) | 7/19 (36.8) | 1/6 (16.7) |

¹ No post-weaning or adult data available for Northern Ireland

- No isolates tested

Table S4.7.13: Resistance in *E. coli* from sheep in England & Wales, Northern Ireland and Scotland in 2014

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | |
|-----------------|---|-------------|-----------|-------------------------------|--------------|-------------|----------|
| | England & Wales | | | Northern Ireland ¹ | Scotland | | |
| | Neonatal | Pre-weaning | Adult | Neonatal | Neonatal | Pre-weaning | Adult |
| Amoxi/Clav | 23/105 (21.9) | 0/12 (0) | 1/5 (20) | 3/25 (12) | 3/21 (14.3) | 3/4 (75) | 2/4 (50) |
| Ampicillin | 58/105 (55.2) | 4/12 (33.3) | 2/5 (40) | 17/25 (68) | 6/21 (28.6) | 3/4 (75) | 2/4 (50) |
| Apramycin | 3/100 (3) | 0/11 (0) | 0/2 (0) | 2/25 (8) | 0/20 (0) | 0/4 (0) | 0/4 (0) |
| Cefotaxime | 3/89 (3.4) | 0/3 (0) | - | - | - | - | - |
| Ceftazidime | 2/89 (2.2) | 0/3 (0) | - | - | - | - | - |
| Chloramphenicol | 26/89 (29.2) | 0/3 (0) | - | - | 0/1 (0) | 0/4 (0) | 0/4 (0) |
| Enrofloxacin | 1/105 (1) | 0/12 (0) | 0/5 (0) | 4/25 (16) | 0/21 (0) | 0/4 (0) | 0/4 (0) |
| Florfenicol | 11/93 (11.8) | 0/4 (0) | 0/2 (0) | 4/25 (16) | 0/21 (0) | 1/4 (25) | 0/4 (0) |
| Neomycin | 7/100 (7) | 1/11 (9.1) | 0/3 (0) | 25/25 (100) | 2/21 (9.5) | 1/4 (25) | 1/4 (25) |
| Spectinomycin | 45/100 (45) | 3/11 (27.3) | 1/2 (50) | - | 5/20 (25) | 2/4 (50) | 0/4 (0) |
| Streptomycin | 38/89 (42.7) | 1/3 (33.3) | 1/1 (100) | - | - | - | - |
| Tetracycline | 71/105 (67.6) | 8/12 (66.7) | 3/5 (60) | 19/25 (76) | 12/21 (57.1) | 4/4 (100) | 2/4 (50) |
| Trimetho/Sulph | 24/105 (22.9) | 1/12 (8.3) | 1/5 (20) | 10/25 (40) | 5/21 (23.8) | 1/4 (25) | 1/4 (25) |

¹ No pre-weaning or adult data available for Northern Ireland

- No isolates tested

Table S4.7.14: Resistance in *E. coli* from sheep in England & Wales, Northern Ireland and Scotland in 2015

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | |
|-----------------|---|-------------|-------------|-------------------------------|--------------|-------------|------------|
| | England & Wales | | | Northern Ireland ¹ | Scotland | | |
| | Neonatal | Pre-weaning | Adult | Neonatal | Neonatal | Pre-weaning | Adult |
| Amoxi/Clav | 19/93 (20.4) | 0/13 (0) | 1/15 (6.7) | 3/9 (33) | 9/37 (24.3) | 1/4 (25) | 1/7 (14.3) |
| Ampicillin | 60/93 (64.5) | 8/13 (61.5) | 4/15 (26.7) | 7/9 (78) | 17/37 (45.9) | 1/4 (25) | 1/7 (14.3) |
| Apramycin | 0/93 (0) | 1/12 (8.3) | 0/6 (0) | 0/9 (0) | 1/35 (2.9) | 0/4 (0) | 0/7 (0) |
| Cefotaxime | 2/74 (2.7) | 0/6 (0) | 0/1 (0) | - | - | - | - |
| Ceftazidime | 1/74 (1.4) | 0/6 (0) | 0/1 (0) | - | - | - | - |
| Chloramphenicol | 14/74 (18.9) | 1/6 (16.7) | 1/1 (100) | - | 0/1 (0) | - | - |
| Enrofloxacin | 2/93 (2.2) | 0/13 (0) | 0/15 (0) | 0/9 (0) | 2/37 (5.4) | 0/4 (0) | 0/7 (0) |
| Florfenicol | 10/74 (13.5) | 0/7 (0) | 1/8 (12.5) | 2/9 (22) | 4/33 (12.1) | 1/4 (25) | 0/7 (0) |
| Neomycin | 20/93 (21.5) | 1/12 (8.3) | 0/8 (0) | 9/9 (100) | 2/37 (5.4) | 1/4 (25) | 1/7 (14.3) |
| Spectinomycin | 58/93 (62.4) | 5/12 (41.7) | 2/6 (33.3) | - | 12/35 (34.3) | 0/4 (0) | 1/7 (14.3) |
| Streptomycin | 51/74 (68.9) | 3/6 (50) | 1/3 (33.3) | - | 1/1 (100) | - | - |
| Tetracycline | 69/93 (74.2) | 8/13 (61.5) | 5/15 (33.3) | 5/9 (56) | 21/37 (56.8) | 1/4 (25) | 4/7 (57.1) |
| Trimetho/Sulph | 32/93 (34.4) | 2/13 (15.4) | 1/15 (6.7) | 4/9 (44) | 6/37 (16.2) | 1/4 (25) | 0/7 (0) |

¹ No pre-weaning or adult data available for Northern Ireland

- No isolates tested

Table S4.7.15: Resistance in *E. coli* from sheep in England & Wales, Northern Ireland and Scotland in 2016

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | |
|-----------------|---|--------------|--------------|-------------------------------|--------------|-------------|-------------|
| | England & Wales | | | Northern Ireland ¹ | Scotland | | |
| | Neonatal | Pre-weaning | Adult | Neonatal | Neonatal | Pre-weaning | Adult |
| Amoxi/Clav | 18/101 (17.8) | 2/26 (7.7) | 3/30 (10) | 24/44 (54.5) | 9/42 (21.4) | 4/13 (30.8) | 0/15 (0) |
| Ampicillin | 60/101 (59.4) | 10/26 (38.5) | 9/30 (30) | 36/44 (81.8) | 19/42 (45.2) | 7/13 (53.9) | 1/15 (6.7) |
| Apramycin | 3/98 (3.1) | 1/17 (5.9) | 1/13 (7.7) | 3/44 (6.8) | 0/42 (0) | 0/13 (0) | 0/15 (0) |
| Cefotaxime | 3/86 (3.5) | 0/11 (0) | - | - | - | - | - |
| Ceftazidime | 2/86 (2.3) | 0/11 (0) | - | - | - | - | - |
| Chloramphenicol | 21/86 (24.4) | 5/11 (45.5) | - | - | - | - | - |
| Enrofloxacin | 5/101 (5) | 0/26 (0) | 1/30 (3.3) | 8/44 (18.2) | 1/42 (2.4) | 0/13 (0) | 0/15 (0) |
| Florfenicol | 7/88 (8) | 2/18 (11.1) | 1/13 (7.7) | 10/44 (22.7) | 1/42 (2.4) | 2/13 (15.4) | 0/15 (0) |
| Neomycin | 20/99 (20.2) | 0/19 (0) | 1/17 (5.9) | 27/27 (100) | 4/42 (9.5) | 1/13 (7.7) | 0/15 (0) |
| Spectinomycin | 51/98 (52) | 6/17 (35.3) | 2/13 (15.4) | - | 13/42 (31) | 3/13 (23.1) | 2/15 (13.3) |
| Streptomycin | 48/87 (55.2) | 6/13 (46.2) | 1/4 (25) | - | - | - | - |
| Tetracycline | 79/101 (78.2) | 13/26 (50) | 11/30 (36.7) | 31/44 (70.5) | 20/42 (47.6) | 9/13 (69.2) | 5/15 (33.3) |
| Trimetho/Sulph | 30/101 (29.7) | 3/26 (11.5) | 2/30 (6.7) | 22/44 (50) | 10/42 (23.8) | 2/13 (15.4) | 0/15 (0) |

¹ No pre-weaning or adult data available for Northern Ireland.

- No isolates tested

S4.8: Clinical surveillance data for *Salmonella*

Table S4.8.1: Resistance in all *Salmonella* from cattle, pigs, sheep, chickens and turkeys (combined) from clinical surveillance in England and Wales, Northern Ireland and Scotland

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | | | |
|-----------------|---|-----------------|-----------------|------------------|---------------|---------------|---------------|---------------|-------------|
| | England & Wales | | | Northern Ireland | | | Scotland | | |
| | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 |
| Ampicillin | 261/1358 (19.2) | 281/1594 (17.6) | 192/1394 (13.8) | 29/257 (11.3) | 16/218 (7.3) | 20/228 (8.8) | 45/147 (30.6) | 61/167 (36.5) | 4/131 (3.1) |
| Amoxi/Clav | 0/1358 (0) | 1/1594 (0.1) | 1/1394 (0.1) | 6/257 (2.3) | 3/218 (1.4) | 5/228 (2.2) | 15/147 (10.2) | 17/167 (10.2) | 2/131 (1.5) |
| Apramycin | 30/1358 (2.2) | 59/1594 (3.7) | 38/1394 (2.7) | 3/257 (1.2) | 2/218 (0.9) | 7/228 (3.1) | 9/146 (6.2) | 10/164 (6.1) | 2/128 (1.6) |
| Cefotaxime | 0/1358 (0) | 1/1594 (0.1) | 1/1394 (0.1) | 0/257 (0) | 0/218 (0) | 1/228 (0.4) | - | - | - |
| Ceftazidime | 0/1358 (0) | 1/1594 (0.1) | 1/1394 (0.1) | 0/257 (0) | 0/218 (0) | 0/228 (0) | - | - | - |
| Ciprofloxacin | 19/1358 (1.4) | 20/1594 (1.3) | 8/1394 (0.6) | 0/257 (0) | 0/218 (0) | 0/228 (0) | - | - | - |
| Chloramphenicol | 107/1358 (7.9) | 95/1594 (6) | 114/1394 (8.2) | 10/257 (3.9) | 6/218 (2.8) | 15/228 (6.6) | - | - | - |
| Gentamicin | 34/1358 (2.5) | 67/1594 (4.2) | 42/1394 (3) | 3/257 (1.2) | 2/218 (0.9) | 7/228 (3.1) | - | - | - |
| Furazolidone | 10/1358 (0.7) | 11/1594 (0.7) | 9/1394 (0.6) | 0/257 (0) | 0/218 (0) | 1/228 (0.4) | - | - | - |
| Nalidixic Acid | 58/1358 (4.3) | 98/1594 (6.1) | 31/1394 (2.2) | 6/257 (2.3) | 12/218 (5.5) | 13/228 (5.7) | 4/144 (2.8) | 4/164 (2.4) | 0/128 (0) |
| Neomycin | 18/1358 (1.3) | 54/1594 (3.4) | 11/1394 (1) | - | - | - | 1/147 (0.7) | 1/167 (0.6) | 1/131 (0.8) |
| Streptomycin | 351/1358 (25.8) | 475/1594 (29.8) | 304/1394 (21.8) | 57/257 (22.2) | 37/218 (17) | 44/228 (19.3) | - | - | - |
| Sulph Compounds | 379/1358 (27.9) | 525/1594 (32.9) | 421/1394 (30.2) | 28/257 (10.9) | 25/218 (11.5) | 36/228 (15.8) | - | - | - |
| Tetracycline | 350/1358 (25.8) | 474/1594 (29.7) | 370/1394 (26.5) | 26/257 (10.1) | 17/218 (7.8) | 18/228 (7.9) | 65/147 (44.2) | 77/167 (46.1) | 7/131 (5.3) |
| Trim/Sulpho | 162/1358 (11.9) | 199/1594 (12.5) | 177/1394 (12.7) | - | - | - | 26/147 (17.7) | 26/167 (15.6) | 0/131 (0) |

- No isolates tested

Table S4.8.2: Resistance in all *Salmonella* from cattle (all ages) from surveillance in England and Wales, Northern Ireland and Scotland

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | | | |
|-----------------|---|--------------|---------------|------------------|------------|-------------|-------------|--------------|------------|
| | England & Wales | | | Northern Ireland | | | Scotland | | |
| | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 |
| Ampicillin | 32/427 (7.5) | 23/346 (6.6) | 36/336 (10.7) | 3/115 (2.6) | 2/81 (2.5) | 2/75 (2.7) | 3/59 (5.1) | 12/73 (16.4) | 0/88 (0) |
| Amoxi/Clav | 0/427 (0) | 0/346 (0) | 0/336 (0) | 1/115 (0.9) | 1/81 (1.2) | 0/75 (0) | 3/59 (5.1) | 11/73 (15.1) | 0/88 (0) |
| Apramycin | 0/427 (0) | 0/346 (0) | 0/336 (0) | 0/115 (0) | 0/81 (0) | 1/75 (1.3) | 0/59 (0) | 0/73 (0) | 1/87 (1.2) |
| Cefotaxime | 0/427 (0) | 0/346 (0) | 0/336 (0) | 0/115 (0) | 0/81 (0) | 0/75 (0) | - | - | - |
| Ceftazidime | 0/427 (0) | 0/346 (0) | 0/336 (0) | 0/115 (0) | 0/81 (0) | 0/75 (0) | - | - | - |
| Ciprofloxacin | 0/427 (0) | 1/346 (0.3) | 0/336 (0) | 0/115 (0) | 0/81 (0) | 0/75 (0) | - | - | - |
| Chloramphenicol | 12/427 (2.8) | 10/346 (2.9) | 23/336 (6.8) | 1/115 (0.9) | 0/81 (0) | 1/75 (1.3) | - | - | - |
| Gentamicin | 0/427 (0) | 0/346 (0) | 0/336 (0) | 0/115 (0) | 0/81 (0) | 0/75 (0) | - | - | - |
| Furazolidone | 2/427 (0.5) | 0/346 (0) | 0/336 (0) | 0/115 (0) | 0/81 (0) | 0/75 (0) | - | - | - |
| Nalidixic Acid | 0/427 (0) | 6/346 (1.7) | 3/336 (0.9) | 2/115 (1.7) | 4/81 (4.9) | 4/75 (5.3) | 1/59 (1.7) | 4/73 (5.5) | 0/87 (0) |
| Neomycin | 1/427 (0.2) | 7/346 (2) | 0/336 (0) | - | - | - | 0/59 (0) | 0/73 (0) | 0/88 (0) |
| Streptomycin | 35/427 (8.2) | 20/346 (5.8) | 41/336 (12.2) | 15/115 (13) | 8/81 (9.9) | 8/75 (10.7) | - | - | 1/87 (1.2) |
| Sulph Compounds | 33/427 (7.7) | 18/346 (5.2) | 37/336 (11) | 3/115 (2.6) | 2/81 (2.5) | 2/75 (2.7) | - | - | - |
| Tetracycline | 35/427 (8.2) | 21/346 (6.1) | 35/336 (10.4) | 3/115 (2.6) | 2/81 (2.5) | 2/75 (2.7) | 9/59 (15.3) | 13/73 (17.8) | 3/88 (3.4) |
| Trim/Sulpho | 9/427 (2.1) | 0/346 (0) | 2/336 (0.6) | - | - | - | 0/59 (0) | 12/73 (0) | 0/88 (0) |

- No isolates tested

Table S4.8.3: Resistance in all *Salmonella* from pigs (all ages) from clinical surveillance in England and Wales, Northern Ireland and Scotland

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | | | |
|-----------------|---|----------------|----------------|------------------|--------------|--------------|------------|-------------|----------|
| | England & Wales | | | Northern Ireland | | | Scotland | | |
| | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 |
| Ampicillin | 139/204 (68.1) | 146/172 (84.9) | 116/160 (72.5) | 11/11 (100) | 9/14 (64.3) | 11/16 (68.8) | 3/3 (100) | 6/10 (60) | 3/5 (60) |
| Amoxi/Clav | 0/204 (0) | 1/172 (0.6) | 1/160 (0.6) | 1/11 (9.1) | 2/14 (14.3) | 3/16 (18.8) | 0/3 (0) | 0/10 (0) | 1/5 (20) |
| Apramycin | 18/204 (8.8) | 44/172 (25.6) | 35/160 (21.9) | 1/11 (9.1) | 2/14 (14.3) | 5/16 (31.3) | 0/3 (0) | 2/10 (10) | 0/5 (0) |
| Cefotaxime | 0/204 (0) | 1/172 (0.6) | 0/160 (0) | 0/11 (0) | 0/14 (0) | 0/16 (0) | - | - | - |
| Ceftazidime | 0/204 (0) | 1/172 (0.6) | 0/160 (0) | 0/11 (0) | 0/14 (0) | 0/16 (0) | - | - | - |
| Ciprofloxacin | 0/204 (0) | 0/172 (0) | 0/160 (0) | 0/11 (0) | 0/14 (0) | 0/16 (0) | - | - | - |
| Chloramphenicol | 75/204 (36.8) | 73/172 (42.4) | 70/160 (43.8) | 4/11 (36.4) | 5/14 (35.7) | 12/16 (75) | - | - | - |
| Gentamicin | 18/204 (8.8) | 48/172 (27.9) | 35/160 (21.9) | 1/11 (9.1) | 2/14 (14.3) | 5/16 (31.3) | - | - | - |
| Furazolidone | 1/204 (0.5) | 0/172 (0) | 0/160 (0) | 0/11 (0) | 0/14 (0) | 0/16 (0) | - | - | - |
| Nalidixic Acid | 2/204 (1) | 1/172 (0.6) | 3/160 (1.9) | 1/11 (9.1) | 2/14 (14.3) | 2/16 (12.5) | 0/3 (0) | 0/10 (0) | 0/5 (0) |
| Neomycin | 8/204 (3.9) | 12/172 (7) | 10/160 (6.3) | - | - | - | 0/3 (0) | 1/10 (10) | 0/5 (0) |
| Streptomycin | 140/204 (68.6) | 155/172 (90.1) | 123/160 (76.9) | 11/11 (100) | 11/14 (78.6) | 14/16 (87.5) | - | - | 0/5 (0) |
| Sulph Compounds | 152/204 (74.5) | 156/172 (90.7) | 137/160 (85.6) | 11/11 (100) | 11/14 (78.6) | 14/16 (87.5) | - | - | - |
| Tetracycline | 152/204 (74.5) | 142/172 (82.6) | 128/160 (80) | 11/11 (100) | 10/14 (71.4) | 14/16 (87.5) | 3/3 (100) | 10/10 (100) | 3/5 (60) |
| Trim/Sulpho | 94/204 (46.1) | 83/172 (48.3) | 76/160 (47.5) | - | - | - | 1/3 (33.3) | 1/10 (10) | 0/5 (0) |

- No isolates tested

Table S4.8.4: Resistance in all *Salmonella* from sheep (all ages) from clinical surveillance in England and Wales, Northern Ireland and Scotland

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | | | |
|-----------------|---|------------|--------------|------------------|-------------|-------------|-------------|-------------|------------|
| | England & Wales | | | Northern Ireland | | | Scotland | | |
| | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 |
| Ampicillin | 0/59 (0) | 4/57 (7) | 11/91 (12.1) | 0/12 (0) | 0/17 (0) | 2/15 (13.3) | 3/26 (11.5) | 1/24 (4.2) | 1/38 (2.6) |
| Amoxi/Clav | 0/59 (0) | 0/57 (0) | 0/91 (0) | 0/12 (0) | 0/17 (0) | 1/15 (6.7) | 3/26 (11.5) | 0/24 (0) | 1/38 (2.6) |
| Apramycin | 0/59 (0) | 0/57 (0) | 0/91 (0) | 0/12 (0) | 0/17 (0) | 0/15 (0) | 1/25 (4) | 0/22 (0) | 1/36 (2.6) |
| Cefotaxime | 0/59 (0) | 0/57 (0) | 0/91 (0) | 0/12 (0) | 0/17 (0) | 0/15 (0) | - | - | - |
| Ceftazidime | 0/59 (0) | 0/57 (0) | 0/91 (0) | 0/12 (0) | 0/17 (0) | 0/15 (0) | - | - | - |
| Ciprofloxacin | 0/59 (0) | 0/57 (0) | 0/91 (0) | 0/12 (0) | 0/17 (0) | 0/15 (0) | - | - | - |
| Chloramphenicol | 0/59 (0) | 0/57 (0) | 11/91 (12.1) | 0/12 (0) | 0/17 (0) | 1/15 (6.7) | - | - | - |
| Gentamicin | 1/59 (1.7) | 0/57 (0) | 0/91 (0) | 0/12 (0) | 0/17 (0) | 0/15 (0) | - | - | - |
| Furazolidone | 0/59 (0) | 0/57 (0) | 0/91 (0) | 0/12 (0) | 0/17 (0) | 0/15 (0) | - | - | - |
| Nalidixic Acid | 0/59 (0) | 0/57 (0) | 0/91 (0) | 0/12 (0) | 1/17 (5.9) | 1/15 (6.7) | 1/25 (4) | 0/22 (0) | 0/36 (0) |
| Neomycin | 0/59 (0) | 0/57 (0) | 0/91 (0) | - | - | - | 0/26 (0) | 0/24 (0) | 1/38 (2.6) |
| Streptomycin | 1/59 (1.7) | 5/57 (8.8) | 14/91 (15.4) | 0/12 (0) | 2/17 (11.8) | 2/15 (13.3) | - | - | 0/36 (0) |
| Sulph Compounds | 1/59 (1.7) | 4/57 (7) | 12/91 (13.2) | 0/12 (0) | 2/17 (11.8) | 2/15 (13.3) | - | - | - |
| Tetracycline | 1/59 (1.7) | 4/57 (7) | 13/91 (14.3) | 0/12 (0) | 1/17 (5.9) | 2/15 (13.3) | 4/26 (15.4) | 3/24 (12.5) | 1/38 (2.6) |
| Trim/Sulpho | 0/59 (0) | 1/57 (1.8) | 0/91 (0) | - | - | - | 0/26 (0) | 0/24 (0) | 0/38 (0) |

- No isolates tested

Table S4.8.5: Resistance in all *Salmonella* from chickens (all ages) from clinical surveillance in England and Wales, Northern Ireland and Scotland*

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | |
|-----------------|---|----------------|----------------|------------------|---------------|---------------|
| | England & Wales | | | Northern Ireland | | |
| | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 |
| Ampicillin | 32/525 (6.1) | 73/768 (9.5) | 21/696 (3) | 14/106 (13.2) | 5/104 (4.8) | 5/110 (4.5) |
| Amoxi/Clav | 0/525 (0) | 0/768 (0) | 0/696 (0) | 4/106 (3.8) | 0/104 (0) | 1/110 (0.9) |
| Apramycin | 12/525 (2.3) | 14/768 (1.8) | 3/696 (0.4) | 2/106 (1.9) | 0/104 (0) | 2/110 (1.8) |
| Cefotaxime | 0/525 (0) | 0/768 (0) | 1/696 (0.1) | 0/106 (0) | 0/104 (0) | 1/110 (0.9) |
| Ceftazidime | 0/525 (0) | 0/768 (0) | 1/696 (0.1) | 0/106 (0) | 0/104 (0) | 0/110 (0) |
| Ciprofloxacin | 3/525 (0.6) | 5/768 (0.7) | 6/696 (0.9) | 0/106 (0) | 0/104 (0) | 0/110 (0) |
| Chloramphenicol | 19/525 (3.6) | 8/768 (1) | 10/696 (1.4) | 5/106 (4.7) | 1/104 (1) | 1/110 (0.9) |
| Gentamicin | 15/525 (2.9) | 18/768 (2.3) | 7/696 (1) | 2/106 (1.9) | 0/104 (0) | 2/110 (1.8) |
| Furazolidone | 7/525 (1.3) | 11/768 (1.4) | 9/696 (1.3) | 0/106 (0) | 0/104 (0) | 1/110 (0.9) |
| Nalidixic Acid | 30/525 (5.7) | 51/768 (6.6) | 18/696 (2.6) | 3/106 (2.8) | 5/104 (4.8) | 5/110 (4.5) |
| Neomycin | 9/525 (1.7) | 28/768 (3.6) | 4/696 (0.6) | - | - | - |
| Streptomycin | 82/525 (15.6) | 117/768 (15.2) | 67/696 (9.6) | 31/106 (29.2) | 16/104 (15.4) | 16/110 (14.5) |
| Sulph Compounds | 101/525 (19.2) | 158/768 (20.6) | 155/696 (22.3) | 14/106 (13.2) | 10/104 (9.6) | 14/110 (12.7) |
| Tetracycline | 76/525 (14.5) | 123/768 (16) | 116/696 (16.7) | 11/106 (10.4) | 4/104 (3.8) | 9/110 (8.2) |
| Trim/Sulpho | 49/525 (9.3) | 100/768 (13) | 93/696 (13.4) | - | - | - |

*Insufficient data from Scotland

- No isolates tested

Table S4.8.6: Resistance in all *Salmonella* from turkeys (all ages) from clinical surveillance in England and Wales, Northern Ireland and Scotland*

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | |
|-----------------|---|----------------|---------------|
| | England & Wales | | |
| | 2014 | 2015 | 2016 |
| Ampicillin | 58/143 (40.6) | 35/251 (13.9) | 8/111 (7.2) |
| Amoxi/Clav | 0/143 (0) | 0/251 (0) | 0/111 (0) |
| Apramycin | 0/143 (0) | 1/251 (0.4) | 0/111 (0) |
| Cefotaxime | 0/143 (0) | 0/251 (0) | 0/111 (0) |
| Ceftazidime | 0/143 (0) | 0/251 (0) | 0/111 (0) |
| Ciprofloxacin | 16/143 (11.2) | 14/251 (5.6) | 2/111 (1.8) |
| Chloramphenicol | 1/143 (0.7) | 4/251 (1.6) | 0/111 (0) |
| Gentamicin | 0/143 (0) | 1/251 (0.4) | 0/111 (0) |
| Furazolidone | 0/143 (0) | 0/251 (0) | 0/111 (0) |
| Nalidixic Acid | 26/143 (18.2) | 40/251 (15.9) | 7/111 (6.3) |
| Neomycin | 0/143 (0) | 7/251 (2.8) | 0/111 (0) |
| Streptomycin | 93/143 (65) | 178/251 (70.9) | 59/111 (53.2) |
| Sulph Compounds | 92/143 (64.3) | 180/251 (75.3) | 80/111 (72.1) |
| Tetracycline | 86/143 (60.1) | 184/251 (73.3) | 78/111 (70.3) |
| Trim/Sulpho | 10/143 (7) | 15/251 (6) | 6/111 (5.4) |

*Insufficient data from Scotland and Northern Ireland

Table S4.8.7: Resistance in all *Salmonella* Dublin from cattle, pigs, sheep, chickens and turkeys (combined) from clinical surveillance in England and Wales, Northern Ireland and Scotland*

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | | | |
|-----------------|---|-------------|-------------|------------------|------------|------------|------------|------------|------------|
| | England & Wales | | | Northern Ireland | | | Scotland | | |
| | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 |
| Ampicillin | 2/286 (0.7) | 4/226 (1.8) | 1/245 (0.4) | 12/110 (10.9) | 6/79 (7.6) | 0/81 (0) | 0/52 (0) | 0/56 (0) | 0/56 (0) |
| Chloramphenicol | 0/286 (0) | 1/226 (0.4) | 1/245 (0.4) | 0/110 (0) | 0/79 (0) | 0/81 (0) | - | - | - |
| Furazolidone | 1/286 (0.3) | 0/226 (0) | 0/245 (0) | 1/110 (0.9) | 0/79 (0) | 0/81 (0) | - | - | - |
| Nalidixic Acid | 0/286 (0) | 5/226 (2.2) | 3/245 (1.2) | 0/110 (0) | 0/79 (0) | 4/61 (4.9) | 4/52 (7.7) | 1/56 (1.8) | 0/55 (0) |
| Neomycin | 1/286 (0.3) | 5/226 (2.2) | 0/245 (0) | - | - | - | 0/52 (0) | 0/56 (0) | 0/56 (0) |
| Streptomycin | 7/286 (2.4) | 9/226 (4) | 4/245 (1.6) | 0/110 (0) | 0/79 (0) | 7/81 (8.6) | 0/52 (0) | 0/56 (0) | - |
| Sulpha/Trim | 2/286 (0.7) | 0/226 (0) | 0/245 (0) | 0/110 (0) | 0/79 (0) | 0/81 (0) | 0/52 (0) | 0/56 (0) | 0/56 (0) |
| Sulph Compounds | 2/286 (0.7) | 0/226 (0) | 0/245 (0) | - | - | - | 0/52 (0) | 0/56 (0) | - |
| Tetracycline | 1/286 (0.3) | 1/226 (0.4) | 1/245 (0.4) | 2/110 (1.8) | 5/79 (6.3) | 0/81 (0) | 0/52 (0) | 0/56 (0) | 3/56 (5.4) |

- No isolates tested

*Minor amendments have been made to the historical data published in past VARSS reports for this data set.

Table S4.8.8: Resistance in all *Salmonella* Typhimurium from cattle, pigs, sheep, chickens and turkeys (combined) from clinical surveillance in England and Wales, Northern Ireland and Scotland**

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | | | |
|-----------------|---|---------------|----------------|------------------|--------------|--------------|-----------|--------------|-----------|
| | England & Wales | | | Northern Ireland | | | Scotland | | |
| | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 |
| Ampicillin | 97/224 (43.3) | 77/165 (46.7) | 100/166 (60.2) | 19/28 (67.9) | 13/24 (54.2) | 15/22 (68.2) | 9/10 (90) | 17/22 (77.3) | 3/3 (100) |
| Apramycin | 2/224 (0.9) | 0/165 (0) | 4/166 (2.4) | * | * | * | * | * | * |
| Chloramphenicol | 82/224 (36.6) | 75.9/165 (46) | 96/166 (57.8) | 10/28 (35.7) | 6/24 (25) | 14/22 (63.6) | - | - | - |
| Furazolidone | 0/224 (0) | 0/165 (0) | 1/166 (0.6) | 19/28 (67.9) | 14/24 (58.3) | 0/22 (0) | - | - | - |
| Nalidixic Acid | 2/224 (0.9) | 2/165 (1.2) | 0/166 (0) | 19/28 (67.9) | 12/24 (50) | 4/22 (18.2) | 1/10 (10) | 4/22 (18.2) | 0/3 (0) |
| Neomycin | 0/224 (0) | 4/165 (2.4) | 1/166 (0.6) | - | - | - | 0/10 (0) | 1/22 (4.5) | 0/3 (0) |
| Streptomycin | 89/224 (39.7) | 85/165 (51.5) | 106/166 (63.9) | 10/28 (35.7) | 13/24 (54.2) | 19/22 (86.4) | - | - | - |
| Sulpha/Trim | 80/224 (35.7) | 53/165 (32.1) | 48/166 (28.9) | 0/28 (0) | 0/24 (0) | - | 1/10 (10) | 1/22 (4.5) | 0/3 (0) |
| Sulph Compounds | 98/224 (43.8) | 80/165 (48.5) | 110/166 (66.3) | - | - | 19/22 (86.4) | - | - | - |
| Tetracycline | 110/224 (49.1) | 77/165 (46.7) | 102/166 (61.1) | 1/28 (3.6) | 2/24 (8.3) | 18/22 (81.8) | 1/10 (10) | 21/22 (95.5) | 3/3 (100) |

- No isolates tested

* Data not available

** Minor amendments have been made to the historical data published in past VARSS reports for this data set.

Table S4.8.9: Resistance in all *Salmonella* other than Dublin and Typhimurium from cattle, pigs, sheep, chickens and turkeys (combined) from clinical surveillance in England and Wales, Northern Ireland and Scotland**

| Antibiotic | No. resistant / No. tested (Percentage resistant) | | | | | | | | |
|-----------------|---|-----------------|-----------------|------------------|--------------|---------------|--------------|--------------|------------|
| | England & Wales | | | Northern Ireland | | | Scotland | | |
| | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 | 2014 | 2015 | 2016 |
| Ampicillin | 233/1837 (12.7) | 292/2198 (13.3) | 220/1986 (11.1) | 19/28 (67.9) | 13/24 (54.2) | 5/125 (4) | 36/85 (42.4) | 44/89 (49.4) | 1/72 (1.4) |
| Apramycin | 29/1837 (1.6) | 64/2195 (2.9) | 40/1986 (2) | * | * | * | * | * | * |
| Chloramphenicol | 33/1837 (1.8) | 53/2198 (2.4) | 52/1986 (2.6) | 10/28 (35.7) | 6/24 (25) | 1/125 (0.8) | - | - | - |
| Furazolidone | 39/1837 (2.1) | 42/2198 (1.9) | 28/1986 (1.4) | 19/28 (67.9) | 4/24 (58.3) | 1/125 (0.8) | - | - | - |
| Nalidixic Acid | 73/1837 (4) | 121/2198 (5.5) | 52/1986 (2.6) | 19/28 (67.9) | 12/24 (50) | 5/125 (4) | 3/82 (3.7) | 0/89 (0) | 0/70 (0) |
| Neomycin | 37/1837 (2) | 70/2198 (3.2) | 44/1986 (2.2) | - | - | - | 1/85 (1.2) | 0/89 (0) | 1/72 (1.4) |
| Streptomycin | 345/1837 (18.8) | 497/2198 (22.6) | 318/1986 (16) | 10/28 (35.7) | 13/24 (54.2) | 18/125 (14.4) | - | - | - |
| Sulpha/Trim | 384/1837 (20.9) | 229/2198 (10.4) | 207/1986 (10.4) | 0/28 (0) | 0/24 (0) | - | 25/85 (29.4) | 25/89 (28.1) | 0/72 (0) |
| Sulph Compounds | 384/1837 (20.9) | 580/2198 (26.4) | 471/1986 (23.7) | - | - | 17/125 (13.6) | - | - | - |
| Tetracycline | 367/1837 (20) | 560/2198 (25.5) | 455/1986 (22.9) | 1/28 (3.6) | 2/24 (8.3) | 13/125 (10.4) | 51/85 (60) | 55/86 (61.8) | 1/72 (1.4) |

- No isolates tested

* Data not available.

** Minor amendments have been made to the historical data published in past VARSS reports for this data set.

Table S4.8.10: Top ten *Salmonella* serovars isolated in Northern Ireland

| Rank | 2014 | 2015 | 2016 |
|------|--------------------------------|-------------------------------|---|
| 1 | Dublin / (321 isolations) | Derby / (437 isolations) | Dublin / (81 isolations) |
| 2 | Mbandaka / (196 isolations) | Mbandaka / (335 isolations) | Mbandaka / (46 isolations) |
| 3 | Kedougou / (128 isolations) | Dublin / (247 isolations) | Muenster / (37 isolations) |
| 4 | Senftenberg / (122 isolations) | Kedougou / (230 isolations) | Typhimurium / (22 isolations) |
| 5 | Montevideo / (115 isolations) | 13,23:i:- / (189 isolations) | Senftenberg / (11 isolations) |
| 6 | 13,23:i:- / (107 isolations) | Senftenberg / (90 isolations) | Derby / (5 isolations) |
| 7 | Typhimurium / (105 isolations) | Enteritidis / (87 isolations) | Tennessee / (4 isolations) |
| 8 | 4,5,12:i:- / (71 isolations) | Typhimurium / (67 isolations) | Diarizoneae 61:-:1,5,7 / (4 isolations) |
| 9 | Derby / (54 isolations) | 4,12:i:- / (58 isolations) | Brandenburg / (2 isolations) |
| 10 | Newport / (44 isolations) | 4,5,12:i:- / (54 isolations) | Choleraesuis / (2 isolations) |

Table S4.8.11: Top ten *Salmonella* serovars isolated in Scotland

| Rank | 2014 | 2015 | 2016 |
|------|-----------------------------------|---------------------------------|-----------------------------------|
| 1 | Dublin / (58 isolations) | Dublin / (64 isolations) | Dublin / (68 isolations) |
| 2 | Typhimurium / (53 isolations) | Typhimurium / (49 isolations) | Typhimurium/ (25 isolations) |
| 3 | Arizonae / (16 isolations) | Arizonae / (17 isolations) | Montevideo/ (17 isolations) |
| 4 | Montevideo / (8 isolations) | Montevideo / (9 isolations) | Bovismorbificans/ (14 isolations) |
| 5 | Enteritidis / (4 isolations) | Salmonella sp. / (7 isolations) | Minnesota/ (17 isolations) |
| 6 | Spp. / (2 isolations) | Derby / (2 isolations) | Arizonae/ (13 isolations) |
| 7 | Mbandaka / (2 isolations) | Enteritidis / (2 isolations) | Mbandaka/ (9 isolations) |
| 8 | Bovismorbificans / (1 isolations) | Salmonella sp. / (6 isolations) | Panama/ (6 isolations) |
| 9 | Group C2 / (1 isolations) | Mbandaka / (2 isolations) | 4,5,12:i:- / (3 isolations) |
| 10 | Aarhus / (1 isolations) | Senftenberg / (2 isolations) | Binza/ (2 isolations) |